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ABSTRACT
Men who have sex with men (MSM) in the United States continue to
experience disproportionate HIV disease burden. Historically, most HIV prevention
research has focused on reducing sexual risk behaviors through individual-level
behavior change interventions. To date, behavioral interventions have not reduced
HIV incidence among MSM and combination prevention approaches that package
behavioral interventions with additive biomedical or structural interventions are now
recommended. The last meta-analysis of HIV behavioral interventions for MSM was
conducted in 2008. Since then sixteen new rigorous trials have been identified. New
evidence and new recommendations justify an updated meta-analysis to identify the
most promising and relevant features of behavioral interventions to be used in new
combination approaches. This study aimed to calculate an updated effect size for
MSM-specific HIV behavioral interventions, identify moderators of effect size,
examine cumulative effect sizes over time, and describe trials that addressed more
than one behavioral outcome (“integrated interventions”). Systematic review and
meta-analysis evaluated effects of 34 randomized controlled trials for 17,872 US
MSM conducted between 1989 and 2014. Behavioral interventions reduced the odds
of sexual risk behavior by 14 percent (OR=.859, 95% CI [0.790, 0.933], p<.001).
Findings suggest behavioral interventions are still somewhat effective to reduce sexual
risk behavior, but the effect size was smaller than effect sizes observed in earlier metaanalyses. Cumulative meta-analysis further demonstrated that intervention effects
gradually declined over time. From 1991 to 2014, the magnitude of the effect size
decreased by 19.5 percent (OR=.719-.859). Reasons for effect size decline are not

clear, but HIV prevention fatigue, inclusion criteria that focus on very high-risk MSM,
choice of comparison condition, and underpowered primary trials likely contribute to
effect size shrinkage. Statistical homogeneity restricted this study’s objective to
reliably detect moderators of effect [Q(33)=39.35, p=.207; I2=16.14]. All moderators
hypothesized a priori were not significant. Post-hoc moderator analyses found
intervention effects to be moderated by age (p<.001), peer delivery (p=.002),
community-level interventions (p=.032), HIV status (p=.019), education (p=.023),
evidence-level (p=.076), retention (p=.09), and MSM subgroup (p=.09). Nine trials
were identified that addressed at least one additional problem behavior other sexual
risk behavior; six trials addressed substance use and three trials addressed HIV testing.
In conclusion, this study provides new evidence that behavioral interventions have
become less effective over time. Development of new combination prevention
packages presents an opportune time to improve and update behavioral interventions.
HIV prevention research would benefit from frequent research synthesis to monitor
effect sizes, identify the most effective intervention components, retire outdated
intervention components, and identify gaps in current research. To our knowledge,
this is the first meta-analysis of HIV behavioral interventions to demonstrate effect
size shrinkage for HIV behavioral interventions using cumulative meta-analysis.
Routine cumulative meta-analysis should be included in research synthesis protocols
to examine and explain effect size shift as new evidence is accumulated.
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CHAPTER 1: INTRODUCTION
Statement of the Problem
The first United States (US) cases of human immunodeficiency virus (HIV)
were reported in 1981. Within a few years, about 50 percent of gay men living in San
Francisco were infected with HIV (Wohlfeiler & Ellen, 2007). There were no HIV
medications, and no government-funded HIV prevention programs. Communities
mobilized through grassroots organizing to distribute information and educational
materials to gay men. Pamphlets, brochures, and media explained that HIV was a
preventable, sexually transmitted infection. Social norms changed in the gay
community and men modified their sexual practices to avoid HIV infection.
Widespread reductions in sexual risk behavior curbed HIV incidence and rates
plummeted (Wohlfeiler & Ellen, 2007).
The majority of HIV prevention research since has focused on reducing sexual
risk behavior to replicate the community-level behavior change seen in the 1980s.
However, behavior change associated with the early HIV crisis slowly eroded over
time, and it is unrealistic to expect similar effects in today’s mature epidemic
(Wohlfeiler & Ellen, 2007). While HIV behavioral interventions have demonstrated
efficacy in reducing sexual risk behavior in small groups of gay, bisexual, and other
men who have sex with men (referred to as men who have sex with men [MSM] in
CDC surveillance systems), effects of interventions are limited by reach and dose and
are not sustained over time. To date, no funded HIV behavioral intervention has
reduced HIV incidence among US MSM. Behavioral interventions, while still
1

necessary, are no longer sufficient for MSM (Coates, 2013). As the HIV epidemic
among US MSM becomes more complex and challenging to control, additional
strategies that can enhance individual-level behavior change interventions are needed.
Combination HIV prevention packages that benefit from combining partiallyeffective behavioral, biomedical, and structural interventions are now recommended.
Combination approaches aim to identify the most effective components of each
intervention and rationally combine them. Scale up of combination approaches
presents an opportune time to review the state of the science of behavioral
interventions and identify the most promising and relevant intervention features. The
last meta-analysis of HIV behavioral interventions for MSM was published in 2008
(Johnson et al., 2008). Since 2008, sixteen rigorous intervention trials have been
published. An updated systematic review was published in 2013 (Higa et al., 2013),
but did not include a meta-analysis. An updated systematic review with meta-analysis
to calculate an updated effect size and identify factors associated with effectiveness is
needed to inform the development of new behavioral interventions.
Epidemiology of HIV among US MSM
Prevention and control of HIV continues to be a major public health challenge
in the United States (Frieden, Foti, and Mermin, 2015). The Centers for Disease
Control and Prevention (CDC) estimates 1.1 million people are infected with HIV
(CDC, 2013a). About 1 in 6 of people infected with HIV do not know they are
infected, and are at higher risk of transmitting their infection to others (CDC, 2013a;
Marks, Crepaz, & Janssen, 2006). HIV incidence has been stable at about 50,000 new
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HIV infections each year (CDC, 2012). However, US MSM continue to experience
disproportionate HIV disease burden compared to other risk groups.
In 2010, 63 percent all persons diagnosed with HIV were MSM (CDC, 2012).
MSM make up about 4 percent of males in the US, but accounted for 78 percent of all
males diagnosed with HIV (CDC, 2012; CDC 2014a). MSM are 44 times more likely
to be infected with HIV than heterosexual males (Purcell et al., 2012). Further, MSM
is the only US risk group where new infections have increased. From 2008 to 2010,
new infections among MSM significantly increased by 12 percent with the steepest
increase (22 percent) among younger MSM aged 13-24 years. Young black MSM
comprise more new HIV infections than any other demographic group (CDC, 2014a),
highlighting a complex epidemic fueled by racial and economic disparities.
MSM of all races and ethnicities also have poorer health outcomes at each
stage of HIV care (e.g. HIV testing, linkage to care, retention in care, adherence to
HIV medications, and viral suppression). Poor care outcomes result in greater HIV
risk because MSM may be unaware of their infection and/or have viral loads high
enough for transmission to sexual partners. In 2010, 78 percent of MSM diagnosed
with HIV were linked to care, 51 percent were retained in HIV care, 49 percent
received antiretroviral therapy, and only 42 percent achieved viral suppression (Singh
et al., 2014). In a 2011 study of MSM in 21 major US cities, 18 percent of MSM were
found to be infected with HIV. One-third of HIV-positive MSM did not know they
were infected (Wejnert et al., 2013).

3

Complex HIV Risk Environment for MSM
Since the beginning of the epidemic, HIV prevention research has been
challenged to demonstrate highly effective interventions for US MSM. The social
context can quickly evolve making previously effective interventions less relevant.
Additionally, MSM-specific HIV epidemics differ from other groups due to multifactorial risk environments. Biological, social, and structural factors interact to create
transmission dynamics that accelerate rapid and efficient transmission of HIV through
sexual networks (Beyrer et al, 2012; Johnson et al., 2010; Sullivan et al., 2012).
Disproportionate HIV disease burden is driven primarily by the high per-act
transmission probability of HIV infection from each encounter of unprotected anal sex
(Baggeley, White, & Boiley, 2010; Beyrer, 2012; Vittinghoff et al., 1999; Patel et al.,
2014). In other words, higher background prevalence of HIV increases the likelihood
that sexual risk behavior will result in infection among MSM (CDC, 2014a).
Higher biological risk is further compounded by person-level factors such as
having multiple sexual partners, frequency of unprotected anal sex, substance use prior
to or before sex, and incident sexually transmitted infection (STI) (Koblin et al.,
2006). Other factors that influence HIV transmission include social or structural
determinants that impact the environment people live in. Stigma and homophobia,
gaps in comprehensive health care, and poor access to condoms and/or HIV testing
challenge HIV prevention norms and create additional stressors for vulnerable MSM
(Altman et al., 2012; Kaufman, Cornish, Zimmerman, & Johnson, 2014; Mayer et al.,
2012). Finally, community-level factors such as higher community viral load due to
undiagnosed HIV infection or poor adherence to HIV medications can vary by sexual
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network (e.g. male sex workers, homeless MSM, substance-using MSM), and make
some communities more vulnerable to HIV exposure and infection (Das et al., 2010;
Mayer et al., 2014).
Combination Prevention Interventions
HIV risk and transmission dynamics among MSM may be too complex to be
effectively addressed by behavioral interventions alone. MSM who intentionally
engage in high-risk sexual practice (despite knowledge of the risks) may require
additional strategies including, but not limited to, individual behavior change. While
newer biomedical interventions are likely to be more effective than behavioral
interventions, they also are not sufficient to prevent HIV if implemented without
behavioral interventions (Coates, 2013). “Combination prevention interventions” are
assumed to maximize prevention through the additive effects of partially-effective
behavioral, biomedical, and structural interventions (Cohen et al., 2013; Dieffenbach
& Fauci, 2011; Kurth, Celum, Baeten, Vermund, & Wasserheit, 2011 Sullivan et al.,
2012;).
UNAIDS (2010) defines combination HIV prevention as:
“The strategic, simultaneous use of different classes of prevention activities
(biomedical, behavioral, social/structural) that operate on multiple levels
(individual, relationship, community, societal), to respond to the specific needs
of particular audiences and modes of HIV transmission, and to make efficient
use of resources through prioritizing, partnership, and engagement of affected
communities.”

5

Combination approaches are now recommended in the National HIV/AIDS Strategy
and in the President’s Emergency Plan for AIDS Relief (US Department of State,
2013; The White House, 2010). To advance new combination approaches, the most
effective components of currently available biomedical, structural, and behavioral
interventions need to be identified. Combination prevention packages can then be
tailored to disrupt the primary drivers of HIV infection in specific populations or
sexual networks.
Biomedical Interventions
Biomedical interventions for MSM take advantage of scientific advances
using antiretroviral therapy (ART) as prevention and hold high promise to curb HIV
transmission. Biomedical interventions, if scaled up, are estimated to have greater
impact on HIV incidence than behavioral interventions - especially for high-risk MSM
resistant to individual behavior change. Recommended biomedical interventions for
US MSM include pre- and post-exposure prophylaxis (PrEP and PEP, respectively)
for uninfected MSM, initiation of ART as “treatment as prevention” (TasP) for HIVpositive MSM, as well as expedited treatment of incident STI. PrEP and TasP are the
most promising biomedical strategies based on estimated efficacy, however they are
relatively recent interventions and are expected to require behavioral components to
optimize adherence, and decrease sexual risk (Cohen et al., 2010; Cohen, et al., 2013;
Grant et al., 2010).
Structural Interventions
Structural interventions aim to influence the environmental variables
associated with risk and create environments that promote HIV prevention norms
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(Kaufman et al., 2014). There is less evidence for these interventions due to
challenges in evaluating slow, structural-level change, yet their hypothesized
contribution to health equity and disruption of key social drivers of HIV risk support
their role in combination approaches (Grossman, Purcell, Rotherum-Borus, &
Veniegas, 2011; Kaufman, et al., 2014; Kurth, Celum, Baeten, Vermund, &
Wasserheit, 2011). Examples of structural interventions include condom distribution
programs, syringe exchange programs, comprehensive health care, and policy changes
to reduce institutional discrimination against lesbian, gay, bisexual, and transgendered
individuals (Breyer et al., 2012; Kaufman et al., 2014).
Behavioral Interventions
This study focuses exclusively on the state of the science of behavioral
interventions. Behavioral interventions have the strongest evidence base for reducing
sexual risk behavior, but they have not shown evidence for reducing incidence
(Sullivan et al., 2012). However, it is logical to continue to support behavioral
interventions because HIV transmission among MSM is driven primarily by the risk
behavior of unprotected anal intercourse (UAI). UAI with serodiscordant partners
(known or unknown HIV-positive partners) and subsequent exposure to high HIV
viral load increases risk of HIV acquisition (Coates, Richter, & Caceres, 2008;
Sullivan et al., 2012). Among US MSM, encounters of UAI increased nearly 20
percent from 2005 to 2011 (Frieden, Foti, & Mermin, 2015; Paz-Bailey et al. 2013).
Behavioral risk data highlight the importance of efficacious sexual risk reduction
interventions that have specific prevention targets such as: 1) reduced UAI, 2)
increased condom use, 3) partner selection based on HIV status, and 4) decreased viral
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load for HIV-positive MSM. Substance use prior to sex, unknown HIV status,
incident STI, and poor treatment adherence among HIV-positive MSM are additional
potential targets for comprehensive or “integrated” behavioral interventions (Coates et
al., 2008; Grossman et al., 2011; Kurth et al., 2011; Mayer et al., 2014; Sullivan,
2012).
Efficacy of Behavioral Interventions
High-quality meta-analytic reviews conducted so far have provided reliable
evidence that behavioral interventions are efficacious in reducing HIV risk among
MSM either by increasing condom use (range: 61% - 81% increase) or decreasing
incidence of UAI (range: 23% - 43% decrease) (Herbst, et al., 2005; Johnson et al.,
2002a; Johnson et al., 2005; Johnson et al., 2008; Sullivan et al, 2012). Intervention
research meta-analyses were further examined by Noar (2008) in a meta-review; the
weighted mean effect sizes for UAI among MSM were consistent with previous
reviews (OR range: 0.65-0.78).
Reviews identified study moderators that produced more favorable effects in
sexual risk reduction interventions. Design variables were shown to most influence
effects. For example, Johnson (2002a, 2008) found count outcomes to be a more
sensitive outcome than dichotomous outcomes because they identify smaller, and
meaningful, reductions in risk behavior. Johnson (2008) also found greater effects in
group-level interventions were associated with shorter intervention spans, better
retention in the intervention condition, and comparison groups with little to no HIV
prevention intervention. Johnson found community-level interventions that addressed
personal skill development were associated with the greatest reductions of UAI, and
8

that effects were associated with random assignment over convenience, shorter recall
periods with longer follow-up periods, higher percentage of non-gay identified MSM,
and higher percentages of white MSM. Herbst et al (2007) found individual-level
interventions based on multiple health behavior theories were associated with greater
effects on sexual risk reduction. Interpersonal skills, awareness, risk and loss
perceptions, and self-efficacy were shown to be important moderators for group-level
interventions, as well as for interventions with multiple sessions and mixed
components (Herbst et al., 2005, 2007; Johnson et al., 2002a, 2007). Theory-based
interventions were more effective than non-theory based interventions (Herbst et al.,
2005; Noar, 2008).
Behavioral interventions are currently supported by the Centers for Disease
Control and Prevention, and evidence-based interventions (EBIs) are published in the
Compendium of Effective Behavioral Interventions (CDC, 2014b). CDC relies on
standardized evaluation of all published interventions using CDC-designed efficacy
criteria (CDC, 2014c). Additionally, CDC routinely publishes research syntheses of
behavioral interventions (Johnson et al., 2002; Johnson et al., 2008; Higa et al., 2013).
All reviews published to date were conducted before recommendations for
combination approaches. Recommendations for combination agendas are driven by
increased evidence pointing to the limitations of behavioral interventions. No review
has examined behavioral interventions in the context of a combination prevention
agenda, and no review has examined how effect sizes may have changed over the past
decade as HIV prevention research has evolved to focus more exclusively on higherrisk MSM subpopulations.
9

Integrated Behavioral Interventions
This study acknowledges that behavioral interventions are necessary, but not
sufficient for HIV prevention. Behavioral interventions can better contribute to
combination prevention agendas if their most effective components are wellunderstood and applied most effectively to the highest risk populations. Higher risk
populations include MSM subgroups identified to have higher burden of HIV and
complex risk factors (e.g. young MSM, black MSM, substance-using MSM). Further,
behavioral interventions may have more impact if they strategically target additional
behavioral outcomes other than sexual risk, otherwise known as syndemic risk factors.
A new area of research is exploring the prevention effects of “integrated
interventions” that address multiple problem behaviors simultaneously (i.e. substance
use, infrequent HIV testing) (Collins, 2015; Crepaz et al., 2014). For example, a
meta-analysis of integrated interventions for HIV-positive persons demonstrated
positive effects for sexual risk reduction, and promising effects for medication
adherence, lending strong evidence for further research into behavioral interventions
that can influence more than one problem behavior at a time (Crepaz et al., 2014).
HIV-negative MSM may also benefit from this approach. The majority of
evidence to date supports only single-behavior sexual risk behavior trials.
Measurement of multiple outcome indicators is not new to the field, and many trials
already include two to three indicators of sexual risk (i.e. UAI, condom use, number of
partners). However, very few trials in the past 25 years have measured convergent
behaviors. Recently, intervention research for HIV-negative MSM has tested
interventions that aim to concurrently reduce sexual and drug risk behaviors for
10

substance users. A recent behavioral intervention using a randomized controlled trial
(RCT) design for young substance-using MSM showed positive effects for substance
use and sexual risk and was classified as an evidence-based intervention by the
Centers for Disease Control (Parsons et al., 2014). Research compiled from other
trials suggests motivational interviewing, cognitive behavioral counseling (CBC),
personalized cognitive counseling (PCC), and empowerment theory influence
intervention effectiveness for substance-using MSM (Kurtz, Stall, Buttram, Surratt, &
Chen, 2013; Morgenstern et al., 2012; Santos et al., 2014; Velasquez et al., 2009).
However, other RCTs found no effect for PCC or CBC (Mansergh et al., 2010;
Schwarcz et al., 2013), and highlight the need for updated research syntheses to clarify
what works best for substance-using MSM (Melendez-Torres & Bonell, 2013).
Increasing HIV testing among high-risk populations, particularly for MSM of
color, is another outcome directly related to improved prevention and care outcomes.
There is less meta-analytic and experimental research specific to increasing HIV
testing. Most studies lack rigor and use observational designs, or have insufficient
sample sizes of MSM (Johnson et al., 2002a). It is known that MSM do not test for
HIV as frequently as recommended, and this observation has stimulated new and
stronger research in this area (Maulsby et al., 2013; Paz-Bailey et al., 2013; Wejnert et
al., 2013). HIV testing is recommended for all MSM at least once per year, but only
67 percent of US MSM reported receipt of an HIV test in the past 12 months (PazBailey et al., 2013). Meta-analytic research demonstrates that knowledge of HIV
status is a robust predictor of reduced risk behavior and increased disclosure to sexual
partners (Marks, Crepaz, & Janssen, 2006). Individuals who test frequently are more
11

likely to identify acute HIV infection earlier, reduce transmission to others, and
expedite linkage to care (van den Berg, Larson, Zimet & Lally, 2014). Social
network-based strategies have been evaluated in primary studies among black MSM,
but findings and designs have varied (Baytop et al., 2014; Ellen et al., 2013; Fuqua et
al., 2011; Halkitis et al., 2011; McCree et al., 2013). Additionally, internet-based
interventions show some evidence for increasing HIV testing among MSM, yet the
research body is too small to be rigorously evaluated (Rhodes et al., 2011; Schnall,
Travers, Rojas & Carballo-Diequez, 2014). Increasing access to convenient, free HIV
testing is a current CDC priority for structural interventions and required through CDC
cooperative agreements with state health departments (CDC, 2015a), but behavioral
interventions will be required to increase individual motivation and receipt of HIV
testing among MSM.

12

CHAPTER 2: STUDY JUSTIFICATION
Study Objectives
Behavioral HIV prevention interventions for MSM are efficacious in reducing
sexual risk behaviors and should continue to be supported and developed. However,
behavioral interventions alone are not expected to reduce HIV incidence. Research
suggests that combination approaches that maximize prevention impact of all available
components to prevent HIV are most promising for disrupting transmission dynamics
in MSM epidemics. New behavioral interventions used in combination approaches
need to be based on the most current evidence, relevant to today’s mature epidemic,
and effective with high-risk MSM. This study aims to identify the most promising
and relevant features of behavioral interventions for MSM to inform the development
of new behavioral interventions.
Objectives of this study are to:
1. Locate and describe experimental outcome studies evaluating effects of
behavioral HIV interventions for US MSM.
2. Summarize effectiveness of interventions to reduce sexual risk behavior using
meta-analysis.
3. Identify study moderators associated with effectiveness.
4. Display cumulative effect sizes over time.
5. Identify experimental trials that examine multiple problem behaviors in
addition to sexual risk reduction such as increased HIV testing and decreased
substance use.
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Study Justification
HIV prevention for US MSM is a persistent public health challenge and new
approaches are urgently needed. Trials testing new combination prevention
approaches are currently underway (e.g. HIV Prevention Trials Network 080 and 073).
To support the role of behavioral interventions in new combination agendas, updated
research syntheses are needed to re-evaluate the current overall effect size, examine
shifts in effect size over time, and identify other behavioral outcomes feasible for
“integrated interventions.”
The last research synthesis was conducted by the Prevention Research
Synthesis Team at the Centers for Disease Control (CDC). Their team published the
last meta-analysis of findings in 2008 (including trials up to 2007) by Johnson et al.
This review included all known RCT designs testing any behavioral intervention that
included some proportion of MSM participants. This review included trials inside and
outside of the US and did not require trials to be specifically designed for MSM (e.g.
trials designed for HIV-positive clinic populations generally have higher proportions
of MSM, but MSM were not the trial focus). In 2013, the team performed a (mostly)
qualitative synthesis of interventions previously evaluated by CDC to meet criteria for
being specifically designed for US MSM (Higa et al., 2013). This systematic review
revealed trends in HIV prevention research and helped explain reasons for failed
efficacy. However, it did not quantitatively summarize findings to produce an updated
effect size. While systematic reviews are essential to research synthesis, they are
limited if they do not calculate updated effect sizes. Quantitative analyses, or metaanalytic results, are required to justify the rationale for ongoing behavioral research in
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MSM, focus research questions based on reliable data, set benchmarks to validate
future research, and examine moderators of effect (Cook et al., 1992; Marsh, Johnson,
& Carey, 2001; Johnson et al., 2008).
Study Hypotheses
This study used systematic review and meta-analysis to synthesize sexual risk
reduction behavioral interventions specifically designed for adult US MSM from
1988-2014. Eligible trials that include integrated interventions such as HIV testing
and substance use were summarized to evaluate the prevalence of integrated
interventions. Hypotheses for this study were:
1. Behavioral interventions are effective to reduce sexual risk behavior
among US MSM.
2. Effects of behavioral interventions are moderated by design variables
(i.e. outcome measure, comparison condition, differential retention, and
intervention time span).
3. An updated meta-analysis will validate effect sizes observed in
previous reviews.
4. Integrated interventions, or trials with multiple behavioral outcomes,
have increased since the last review.
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CHAPTER 3: Methodology
Systematic Review
A systematic review of the HIV prevention literature was conducted to locate
and retrieve trials evaluating behavioral interventions for US MSM and published
between 1988 and 2014. The systematic review procedure was informed by
guidelines from The Cochrane Handbook for Systematic Reviews of Interventions
(Higgins & Green, 2008) and Preferred Reporting Guidelines for Systematic Review
and Meta-Analysis (Moher, Liberati, Tetzlaff, Altman & PRISMA Group, 2009).
The review was influenced by previous high-quality meta-analyses that have
been used to inform evidence-based recommendations for HIV prevention (Herbst et
al., 2007; Johnson et al., 2008; Higa et al 2013). The present review differs from other
reviews because it excludes interventions designed exclusively for HIV-positive
MSM, and it only includes trials specifically designed for MSM. Trials specific to
HIV-positive MSM did not fall under this study’s classification as HIV prevention to
prevent HIV acquisition. Following Higa et al.’s approach, only trials designed for
MSM were included to understand intervention effects and past research specific to
this population. This review updates the qualitative synthesis of Higa et al. (2013) by
adding randomized controlled trials from 2011-2014, and also providing a metaanalytic synthesis of trials published from 1988-2014.
Inclusion Criteria
Trials were reviewed for relevance based on four major criteria: 1) types of
participants (i.e., MSM), 2) types of outcome measures (i.e., HIV risk behaviors), 3)
types of interventions (i.e., behavioral interventions), and 4) types of trials (i.e., RCT
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design). Trials were considered in scope if they examined any behavioral intervention
aimed at reducing sexual risk behaviors for HIV transmission among US MSM. Trials
were eligible for inclusion if they were: 1) behavioral interventions to prevent
acquisition of HIV, 2) specifically designed for adult MSM, 3) conducted in the
United States, 4) tested using a randomized controlled trial, 5) measured at least one
behavioral or biological outcome variable of relevance (e.g., HIV or STI incidence,
anal sex without a condom, number of sexual partners, condom use for anal sex), and
6) published in a peer-reviewed journal between 1988 and 2014.
Exclusion Criteria
Review was restricted to interventions focused on the primary prevention of
HIV infection among adult MSM. This restriction assumes there may be important
differences between HIV-negative MSM and HIV-positive MSM, as well as
differences between adult MSM and adolescent MSM, in the underlying processes of
behavior change (Herbst et al., 2007). Inclusion of such trials may have increased
statistical heterogeneity or obscured effects of prevention interventions on the
population of interest: HIV-negative adult MSM. Trials were excluded if they: 1)
focused on HIV-positive MSM (i.e., 100 percent HIV-positive sample) and secondary
prevention of HIV transmission to sexual partners, 2) included some proportion of
MSM participants, but were not specifically designed for adult MSM (i.e., less than 95
percent MSM), and 3) focused on adolescent MSM (i.e., mean sample age of <18
years). Trials that did not report enough statistical information to calculate an effect
size were excluded after attempts to contact study authors failed to produce necessary
data.
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Types of Participants
Trials were included if participants were adult men over 18 years old who
reported sex with other men and lived in the United States. MSM were included
regardless of race/ethnicity, sexual identity (e.g., gay, bisexual, homosexual,
heterosexual, etc.), or other demographic characteristics. Trials that included some
proportion of HIV-positive MSM in the sample were included except when the trial
exclusively focused on HIV-positive MSM.
Types of Interventions
Trials were included if they were behavioral interventions designed to prevent
the acquisition of HIV infection by changing individual sexual risk behaviors through
modeling, demonstration, role-playing, risk reduction planning, group or individual
counseling, or other behavioral intervention method. Individual-level, group-level,
couples-level, and community-level interventions were included. Behavioral
interventions were defined to be different than provision-of-information-only
interventions that aim to change knowledge, attitudes, or norms only (e.g., increasing
HIV knowledge), and different than environmental or structural interventions that aim
to change the physical or social environment to promote health and prevent disease
(e.g., mass media campaigns, policy change) (The Community Guide, 2008). Trials
that focused only on psychological moderators of risk behavior, cognitive outcomes,
or affective outcomes (e.g., distress, depression) were considered out of scope.
Types of Outcome Measures
Review was restricted to trials that measured intervention effects on behaviors
known to influence risk of HIV acquisition among MSM (e.g., anal sex without a
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condom, number of male sexual partners, frequency of condom use for anal sex), or
trials with biological outcomes such as HIV or STI incidence. Operational definitions
of primary outcome variables are not standardized among HIV prevention trials
(Johnson et al., 2002b). The most frequently reported measures used for sexual risk
behavior in most at-risk populations are frequency of unprotected sex, condom use,
and number of sex partners (Johnson et al., 2002b). Unprotected sex is often reported
using dichotomous (i.e., proportion of participants reporting any unprotected sex
within the recall period) and count measures (i.e., number of partners, or number of
episodes for unprotected sex within the recall period).

Trials were eligible for review

if they reported at least one measure of sexual risk behavior that was specific to maleto-male sexual contact.
Types of Trials
Trials were eligible if they included a relevant outcome variable and
methodological rigor as demonstrated by study design. Only trials that used a
randomized controlled trial (RCT) with independent comparison group were included
for review. No exclusions were made by type of comparison group. All other study
designs, including rigorous quasi-experimental, were excluded. This restriction was
intended to ensure that the evidence under review had a high level of methodological
rigor (Guyatt et al., 1995; Stephenson & Irmie, 1998). RCT designs are experimental
studies where subjects are randomly allocated to intervention (i.e., treatment) or
comparison (i.e., control) group, and then followed under controlled conditions
(CEBR, 2015). When implemented with high quality, RCTs are better able than other
designs to attribute observed effects to the intervention condition while also
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minimizing potential sources of bias (Higa et al., 2013; CEBR, 2015). Most
interventions classified as Evidence-Based Interventions (EBI) by CDC are tested
using RCT design to ensure internal validity before disseminating evidence-based
interventions into real-world settings.
Search Strategy
The peer-reviewed published HIV prevention literature was systematically
searched from April 2015 to June 2015 to locate trials that met eligibility criteria.
Five electronic databases were searched from January 1988 to April 2015: 1) PubMed,
2) EMBASE, 3) CENTRAL, 4) PsycInfo, and 5) CINAHL. The year of 1988 was
chosen as the start date to capture the earliest known intervention trials and is
consistent with previous reviews (Johnson et al., 2008). Search sensitivity was
prioritized over precision; no restrictions by country, geography, outcomes, or
language were applied. After electronic searches, hand searches of five key journals
(AIDS & Behavior, American Journal of Public Health, AIDS Education &
Prevention, Journal of the Association of Nurses in AIDS Care, and AIDS Care) were
conducted to locate articles published between January 2014 to December 2014 that
may have been missed by electronic searches due to indexing lags. References from
prior systematic reviews and meta-analyses were reviewed until no new references
were identified.
Keywords, search strings, and search strategies varied by electronic database.
Three search strings were developed to systematically search the literature: 1) MSM
string (the population filter), 2) HIV/AIDS prevention string (the disease filter), and 3)
RCT string (design filter). The population filter and disease filter were specified using
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controlled vocabulary (e.g., MeSH terms for PubMed or EMTREE terms for
EMBASE) to retrieve articles that may be indexed by different words. Controlled
vocabulary terms were identified through a comprehensive approach. Search
strategies from previous reviews and consultations with experts trained in Cochrane
Systematic Reviews helped to inform the first draft of each string. Strings were then
refined by identifying trials known to fit eligibility criteria and looking up their index
terms, common text words, and subject words. Other terms were identified using
search tools in each database (e.g., MeSH database in PubMed) to customize the
search to each database. Once key terms were identified, terms were exploded to
generate more specific terms or synonyms to include in each search string. Boolean
operators joined together controlled vocabulary terms, free-text terms, and identified
synonyms for the final string. The published “Cochrane Highly Sensitive Search
Strategy for Identifying Randomized Trials in Medline” (Higgins & Green, 2008) was
used in its exact form to filter trials by RCT design in PubMed. This string was
adapted for use in other databases. A detailed Search Strategy document (Appendix
A) details the search strategy, final strings, date and time of search, results, and final
number of trials located for each database searched. Citations and abstracts for
located trials were downloaded from each database and exported into an EndNote X7
file for reference management. Duplicates were deleted. Titles and abstracts were
scanned by the primary author to validate they met inclusion criteria. Trials that did
not meet inclusion criteria were discarded into an Excluded folder. Full manuscripts
that met inclusion criteria were downloaded for data extraction.
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Data Extraction
A study protocol was developed to guide data extraction (Appendix B) and
was informed by The Community Guide’s Data Abstraction Form (2008). Data
extraction forms collected a wide range of information on study descriptors (e.g.,
participant characteristics, study characteristics, design characteristics), study results
(e.g., primary and secondary outcomes, significance, study retention), statistical
information (e.g., descriptive data to calculate effect sizes), and methodological
quality (e.g., CDC’s Prevention Research Synthesis criteria). Two independent coders
extracted trial data using standardized forms; one coder completed 50 percent of
records. Disagreements were resolved by discussion until consensus was reached; a
methodological expert was consulted as needed.
Data to Test Study Hypotheses
Moderating variables specified a priori were extracted to test study
hypotheses. Based on Johnson et al. (2008), four variables were selected and coded
for moderator analyses: 1) effect measure type, 2) intervention time span, 3)
differential retention by group, and 4) control condition. A second hypothesis
specified that studies with multiple behavioral outcomes have increased since 2007.
To test this hypothesis, a dichotomous variable was created to indicate (yes/no) if the
study reported multiple behavioral outcomes (e.g., substance use and sexual risk, or
HIV testing and sexual risk). If multiple outcomes were found, study coders described
them in a free-text field.
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Assessment of Methodological Quality
Methodological quality was assessed according to CDC’s Prevention Research
Synthesis (PRS) criteria for evidence-based interventions (CDC, 2014c). The PRS
team was created in 1996 to systematically review and summarize HIV behavioral
intervention research. PRS aims to translate scientific evidence into evidence-based
recommendations for HIV prevention (Higa et al., 2013; Lyles, Crepaz, Herbst, &
Hay, 2006). PRS efficacy criteria were informed by efficacy criteria used in other
projects such as the Community Guide and Grades of Recommendation, Assessment,
Development, and Evaluation (GRADE). PRS prioritizes assessing the internal
validity of trials “to ensure a reasonable level of confidence that the observed changes
can be attributed to the intervention” (Higa et al., 2013; Lyles et al., 2006). Efficacy
criteria can be applied to individual, group, couples, or community-level behavioral
interventions and are comprised of five major domains: Intervention Description (e.g.,
clarity), Quality of Study Design (e.g., comparison arm, allocation), Quality of Study
Implementation and Analysis (e.g., follow-up time, retention rate, alpha level, sample
size), Strength of Evidence (e.g., statistically significant result [p<.05], relevant
outcome, no harmful effects), and Additional Limitations to Evaluate (e.g., fatal flaws
such as differential retention or substantial missing data). Studies that meet all criteria
are classified as Evidence-Based Interventions either at the Good Evidence level or
Best Evidence level. In 2013, Higa et al. of the PRS team reviewed MSM-specific
interventions previously reviewed in the PRS database to better understand
methodological challenges to demonstrating efficacy of HIV behavioral interventions
for MSM. Higa et al. classified each trial into one of four mutually exclusive
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categories: Evidence-Based Interventions (EBIs: trials that meet all efficacy criteria);
Rigorous Non-EBIs (trials that meet all efficacy criteria except for a significant
positive finding); Positive Non-EBIs (trials that reported a significant positive finding,
but did not meet at least one other criterion); and Other Non-EBIs (trials that did not
report significant positive finding and did not meet at least one other PRS criterion).
This review uses original PRS criteria and Higa’s additional four-level categorization
system (Appendix C). Higa et al.’s ratings were entered into the data extraction form
for trials prior to 2011. For trials not already rated by Higa, coders applied PRS
criteria and resolved any disagreement by discussion.
Protocol Modifications
The original study protocol was modified during data extraction to make three
important changes. The original scope of the review included any behavioral
intervention trial with a comparison arm that targeted MSM with enough information
to calculate an effect size. Upon reviewing the literature, three changes were made to
the scope: 1) include only trials designed specifically for MSM (e.g., MSM
representing at least 95 percent of the sample instead of trials that included >50
percent MSM), 2) exclude trials designed specifically for HIV-positive MSM (e.g.
HIV-positive MSM comprising 100 percent of the sample), and 3) exclude any study
that was not RCT (e.g., exclude quasi-experimental designs, even those with
comparison groups). Changes were based on narrowing the scope of the review to
best understand the effects of diverse interventions on MSM while minimizing threats
to validity. Statistical challenges were found when attempting to isolate effects of the
intervention on MSM if trials included non-MSM (e.g., reducing study weight to only
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reflect the MSM subset), concerns emerged about increasing statistical and clinical
heterogeneity if HIV-positive MSM were included, and concerns emerged about
decreased methodological quality if non-RCT designs were included.
Statistical and Other Software
Microsoft Excel (2007), EndNote (X7), Biostat Comprehensive Meta-Analysis
(Version 3), and SPSS (Version 22.0) were used to enter, manage, and analyze data
for the systematic review, meta-analysis, and other data analyses. The data extraction
protocol and standardized forms were created in Microsoft Excel. Descriptive
statistics were calculated in Microsoft Excel and SPSS. Reference management was
conducted exclusively in EndNote. Meta-analyses, moderator analyses, cumulative
analyses, outlier analyses, and publication bias analyses were conducted in Biostat
Comprehensive Meta-Analysis (Borenstein, Hedges, Higgins, & Rothstein, 2015).
Statistical Analyses
Meta-Analysis
Meta-analysis was used as the primary analysis to synthesize results across
trials and calculate a standardized effect size. One overall meta-analysis was
conducted using the primary outcome from each study. Meta-regressions and
subgroup analyses examined potential moderators of the overall effect size.
Additional analyses included cumulative meta-analysis to calculate the cumulative
effect size by year, homogeneity tests of the effect size distribution, analyses of
publication bias, and sensitivity analysis for outlier analysis.
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Outcome Measures
Outcomes used in this meta-analysis included: 1) mean number of episodes of
UAI (k=14), 2) proportion of MSM reporting any UAI (k=18), 3) or mean number of
male sexual partners for any anal intercourse (k=2). This study focused on
unprotected anal intercourse (UAI) as the outcome of interest. UAI is the most
epidemiologically important HIV risk behavior for MSM, and UAI data were
available for most trials. Number of male sexual partners for anal intercourse was
used only when the authors specified it as a primary outcome, and there was no
available secondary outcome about UAI (k=2). This outcome is imperfect as it may
measure partners for unprotected sex or protected sex, and may not be a reliable
indicator of true HIV risk. Despite this limitation as an outcome measure, these
studies were included because they contributed some meaningful measure of sexual
risk.
Meta-analysis requires an assumption of independence between trials; only one
outcome per trial is appropriate for calculating an overall effect size (Borenstein,
Hedges, Higgins, & Rothstein., 2009). The primary outcome specified by trial authors
was used to calculate one effect size for each trial. Fifteen studies reported multiple
outcomes related to the same sexual risk construct, but did not specify a primary
outcome. For these studies, the most precise outcome associated with highest risk of
HIV acquisition was used. UAI confers the greatest risk for HIV and previous reviews
have revealed count outcomes to be more sensitive than dichotomous outcomes
(Johnson et al., 2008). Based on this rationale, mean number of UAI episodes was
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specified as primary outcome. If count-level UAI data were not available, the
proportion of any UAI was used.
Outcome variables used for meta-analysis did not discriminate between
insertive or receptive anal intercourse (i.e., sexual position), primary or non-primary
partners, or partner’s HIV status (i.e., serodiscordant or seroconcordant partners).
Specific results about behaviors with certain partners, or specific results about
behaviors by sexual position (i.e., insertive vs. receptive anal intercourse) were used
when more general results were unavailable. When UAI results were only presented
by sexual position (e.g., insertive UAI vs. receptive UAI), results describing receptive
anal intercourse were used because it is a higher risk behavior than insertive anal
intercourse (k=2). When UAI results were only presented by primary vs. non-primary
partner, non-primary partner results were used (k=1) under the assumption this
situation conferred greater risk. Risk behavior outcomes specific to vaginal sex, oral
sex, or sex with female partners were excluded from analysis. For trials that reported
sexual behavior with both male and female partners as primary outcomes, secondary
outcomes specific to anal intercourse with male partners were used (k=2).
Three trials tested more than two experimental conditions against one control
group (Dilley et al., 2007; Hirschfield et al., 2012; Shoptaw et al., 2005). One
approach to multiple comparisons is to split the comparison group into equal parts to
compare each intervention to a control group. While this can preserve the assumption
of independence, it can also create a bias towards homogeneity, especially if the study
is large (Borenstein et al., 2009). While only one of the three studies was large, an
alternative protocol was used. For the three studies, the most relevant intervention
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condition was selected to compare to the control. Descriptive data for the excluded
condition/s were not used in the meta-analysis and overall sample size for the study
was adjusted.
For studies that reported outcomes at multiple time points, the last follow-up
assessment was used to calculate effect sizes. Last follow-up was selected to examine
sustained intervention effects. Most trials used a 3, 6, or 12 month follow up. Followup period was included as a moderator variable to statistically examine its relationship
to the overall effect size.
Calculation of Effect Sizes
Effect sizes for each trial were calculated using the odds ratio (OR) for
dichotomous measures and standardized mean difference (SMD) for count-level
measures. Estimates of effect size were calculated based on descriptive data (e.g.,
means, standard deviations, frequencies, or proportions). When descriptive data were
not available in any published report, requests for additional trial data were sent to trial
authors. If data were not obtained from trial authors, the trial was excluded from
analysis (k=4).
One measure of effect size is required to estimate the overall pooled effect
size. To be consistent with previous meta-analyses using RCT designs, the OR was
chosen as the common metric. SMDs were converted to the OR for the main metaanalysis. Disadvantages to using the OR for meta-analysis are that odds are less
intuitive than risk, ORs are centered around 1, and ORs are problematic when cell size
equals zero (Lipsey & Wilson, 2001). Advantages are that ORs have favorable
mathematical properties, standard errors are easy to calculate, and they are commonly
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reported in epidemiological research (Lipsey & Wilson, 2001; Borenstein et al., 2009;
Higgins & Green, 2008). Calculations for odds ratios were conducted using the
natural logarithm scale (lnOR). The lnOR, standard error (SE) of the lnOR, and
confidence limits were calculated to generate values that are used in each step of the
meta-analysis (Borenstein et al., 2009). Each lnOR was multiplied by its inverse
variance weight, weighted lnORs across trials were summed, and then divided by the
sum of the weights (Lipsey & Wilson, 2001). After meta-analysis, the results were
converted back into OR units for display purposes.
Odds Ratios
For trials reporting dichotomous outcomes (e.g. frequencies or proportions),
the odds ratio (OR) was calculated to estimate intervention effect. The OR was
calculated for each cross-product ratio from 2x2 tables representing the frequency of
UAI in the intervention group as compared to the control group at last follow-up
(Herbst et al., 2007; Haddock, Rindskopf, & Shadish, 1988).
The computational formula for an odds ratio is (Borenstein et al., 2009):
𝐴𝐷

OR =𝐵𝐶

Each OR was then transformed to the log scale using the natural logarithm
(lnOR) to obtain the log odds ratio (Johnson, 2002b; Bornstein et al., 2009):
𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 = ln(𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜)
with approximate variance:
𝑉𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 =
and approximate standard error:
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1 1 1 1
+ + +
𝐴 𝐵 𝐶 𝐷

𝑆𝐸𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 = √𝑉𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜
As specified previously, the log odds ratio and its variance were used to
generate the summary effect, confidence limits (LL=lower limits; UL=upper limits),
and other measures in log units. Each value was then converted back to the odds ratio.
Log odds ratios, variances, and 95% confidence intervals were transformed back to
ORs by using the formula (Borenstein et al, 2009):
𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 = exp(𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜),
𝐿𝐿𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 = exp(𝐿𝐿𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜) ,
𝑈𝐿𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜 = exp(𝑈𝐿𝐿𝑜𝑔𝑂𝑑𝑑𝑠𝑅𝑎𝑡𝑖𝑜) .
Standardized Mean Differences
For trials with count-level outcomes (e.g., mean number of UAI events),
standardized mean differences (SMD) and variances were calculated to estimate
intervention effects (Johnson et al., 2002b; Bornstein et al., 2009). SMDs are the more
appropriate option (as opposed to raw mean differences) when studies use different
instruments to measure the outcome. Unadjusted, descriptive data (e.g., means,
standard deviations, standard errors, frequencies, proportions) were used to calculate
effect sizes. If measures of variance (i.e., standard deviation or standard error) were
not reported, standard deviation was obtained by using sample sizes for intervention
and control groups and the independent groups exact p-value. From these values, a tvalue can be computed to obtain standard error which can be converted to standard
deviation (Higgins & Green, 2008). The SMD (or Cohen’s d) was the mean
difference of intervention and control at follow-up divided by the within-group pooled
standard deviation. Cohen’s d is calculated by the formula: (Borenstein et al., 2009):
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𝑑=

𝑀1 − 𝑀2
𝑆𝑤𝑖𝑡ℎ𝑖𝑛

The numerator values represent the sample means in each group and the
denominator represents the pooled within-groups standard deviation calculated as:
(𝑛1 − 1)𝑆12 + (𝑛2 − 1)𝑆22
𝑆𝑤𝑖𝑡ℎ𝑖𝑛 = √
𝑛1 + 𝑛2 − 2
The variance of d is approximated by:
𝑉𝑑 =

𝑛1 +𝑛2
𝑛1

𝑑2

+ 2(𝑛

1 +𝑛2)

.

The standard error of d is the square root of 𝑉𝑑 given as:
𝑆𝐸𝑑 = √𝑉𝑑 .
SMD was converted to the OR to achieve a common metric, but has been
shown to be upwardly biased when applied to small samples (Hedges, 1981). Hedges’
g corrects for this bias (Lipsey & Wilson, 2001) with a correction factor (J), and
provides an alternative effect size to Cohen’s d. Hedges’ g was additionally calculated
by the following formula:
𝐽 =1−4

3

,

𝑑𝑓 −1

𝑔 = 𝐽 × 𝑑,
𝑉𝑔 = 𝐽2 × 𝑉𝑑 ,
and
𝑆𝐸𝑔 = √𝑉𝑔 .
To transform data, Cohen’s d was converted to the logs odds ratio by
standardized formulas (Johnson, 2002b):
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SMD=√3 × [ln(𝑎) + ln(𝑑) − ln(𝑏) − ln(𝑐)] ÷ 𝜋,
1

1

1

1

Var(SMD)≈3/𝜋 2 × [𝑎 + 𝑏 + 𝑐 + 𝑑],
ln OR=
𝑉𝑎𝑟(𝑙𝑛𝑂𝑅) =

𝜋
√3
𝜋2
3

× 𝑆𝑀𝐷,
× 𝑉𝑎𝑟(𝑆𝑀𝐷).

Intraclass Correlation Coefficient
For trials that used the community as the unit of assignment (i.e. communitylevel interventions, k=3), an estimate of the intraclass correlation coefficient (ICC)
was applied to adjust study weights when cluster data was available. The ICC
estimates the relative variability within and between clusters (Donner & Koval, 1980;
Higgins & Greene, 2008). If the ICC is not accounted for, the variance of the
intervention effect may be underestimated and the weight will be overestimated
(Johnson et al., 2008). ICCs are not frequently available in study reports and it is
common to use ICCs from other studies (Higgins & Green, 2008). To reduce each trial
to the “effective sample size,” an ICC of .005 was assumed because this value was
cited in one community-level intervention report (Kelly et al., 1997; Johnson et al.,
2002). To calculate the effective sample size, the original sample size is divided by
the design effect:
𝐷𝑒𝑠𝑖𝑔𝑛𝐸𝑓𝑓𝑒𝑐𝑡 = 1 + (𝑀 − 1)𝐼𝐶𝐶,
where M is the average cluster size. Calculation of average cluster size was not
possible for two of three trials due to missing cluster data and unadjusted results were
used in the meta-analysis.
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Model of Analysis
Variance was modeled using fixed and random effects models. Both models
were specified a priori for comparison. Previous HIV prevention reviews have
revealed highly homogeneous distributions so it was assumed that random and fixed
models would yield identical results for the primary meta-analysis (Johnson et al.,
2008.). Fixed effects models assume the variance is subject-level sampling error only
(not study level variance) and are generally used for homogenous distributions.
Random effects models are more conservative and assume that the variance has
random study-level variance in addition to random subject-level sampling error. An
additional random effects model was specified due to possible heterogeneity of trial
subgroups, outcome measures, intervention content, and design variables (Hedges &
Olkin, 1985). To fit a random effects model, non-iterative methods of the moment
were used (Lipsey & Wilson, 2001). Biostat’s Comprehensive Meta-Analysis was
used to provide fixed and random effects mean effect sizes.
Calculations for the Mean Effect Size
A mean effect size, or summary effect size across studies, was calculated to
obtain the most precise estimate of the mean using both fixed and random models.
Before calculating the mean effect size, each effect size (lnOR) was weighted by the
inverse of its variance to correct sample size bias. Effect sizes based on larger
samples provide more precise estimates because the sampling error is smaller.
Optimal weights are achieved by using the standard error (Hedges & Olkin, 1985).
Individual studies were weighted by their respective sample sizes after all study effect
sizes had been transformed to the lnOR. Each study was assigned a weight that was
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the inverse of its variance, or the “inverse variance weight” (Lipsey & Wilson, 2001).
The study weight is computed by this formula where VYi is the within-study variance
for the study (i) Borenstein et al., 2009):
1
𝑉𝑌 𝑖

𝑊𝑖 =

For random effects analyses, study weights included within-study variance and
an estimate of the between-studies variance (T2).
The weighted mean effect size (M) was then calculated by multiplying each
effect size by its weight, summing the products (WiYi), and then dividing by the sum of
the weights (Borenstein et al., 2009):
∑𝑘𝑖=1 𝑊𝑖 𝑌𝑖
𝑀=
∑𝑘𝑖=1 𝑤𝑖
The variance of the mean effect size was calculated as the reciprocal of the
sum of the weights (Borenstein et al., 2009):
𝑉𝑀 = ∑𝑘

1

𝑖=1 𝑊𝑖

,

and the standard error of the mean effect size was calculated by taking the
square root of the variance (Borenstein et al., 2009):
𝑆𝐸𝑀 = √𝑉𝑀 .
Confidence intervals (CIs) were set at 95% to examine the precision of the
mean effect size and individual study effect size estimates. CIs demonstrate precision
by providing the range of possible values for the effect size; a 95% confidence interval
implies that the population mean effect size has a 95% probability of being in between
the lower and upper bound of the CI. CIs were calculated by multiplying the standard
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error by a critical z value to represent the proposed confidence level, adding the
product to the point estimate for the upper limit, and subtracting the product from the
point estimate for the lower limit. Upper (UL) and lower limits (LL) were given by
these formulas (Borenstein et al., 2009):
𝐿𝐿𝑀 = 𝑀 − 1.96 × 𝑆𝐸𝑀 ,
𝑈𝐿𝑀 = 𝑀 + 1.96 × 𝑆𝐸𝑀 .
To test the null hypothesis that the mean effect size is zero, a Z-value was
calculated (Borenstein et al., 2009):
𝑀

𝑍 = 𝑆𝐸 ,
𝑀

and a p-value was given for the two-tailed test by (Borenstein et al., 2009):
𝑝 = 2[1 − (Φ(|𝑍|))],
where Ф(Z) represents the normal cumulative distribution.
Interpretation of Effect Sizes
Effect sizes are the primary result reported. After all calculations were
conducted using the lnOR, values were converted back to the OR for display purposes.
ORs are centered around 1 instead of zero with 1 indicating no relationship, or a null
effect (Lipsey & Wilson, 2001). For behavioral trials in this study, ORs between 0
and 1 favor the intervention condition and indicate a positive effect. ORs greater than
1 favor the comparison group. ORs of 1 indicate no difference between intervention
and comparison group. ORs are interpreted with their corresponding 95% CI to
indicate the precision of the estimate. Wider confidence intervals indicate a less
reliable estimate. Wider confidence intervals are associated with higher relative
standard error and smaller samples. Confidence intervals that include the null value of
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1 indicate there is insufficient evidence to detect a significant difference between
groups. P-values were considered significant at the p<.05 level.
Cumulative Meta-Analysis by Year
Cumulative meta-analysis was performed to display how the weight of
evidence has shifted over time. Cumulative meta-analyses are conducted by running a
meta-analysis with one study, then repeating it with a second study added, and
repeating again until all studies are included. Studies were sorted chronologically by
year from oldest to newest, and overall percent change from earliest to latest year was
calculated. Effect size change was also calculated from the earliest statistically
significant cumulative effect size to the latest effect size. Forest plots were produced
for visual examination of effect size with each new study added, and shifts in effect
size over time. Cumulative meta-analysis is primarily a method for displaying results
of a series of separate meta-analyses in one forest plot (Borenstein et al., 2009). To
better understand how the evidence has accumulated over time, study year was also
coded as a moderator and used in meta-regression to statistically evaluate the
relationship between effect size and year.
Heterogeneity of Variance
Heterogeneity of variance implies that the effect size is not consistent across
studies. Observed heterogeneity can occur because of random error (e.g. spurious or
excess variation) or systematic differences (e.g. true variation) that require further
analysis such as in the case of moderator variables. Variation between effect sizes was
first examined by visually analyzing the forest plot to detect large differences between
point estimates (OR) and the extent of the CI overlap. Large differences between ORs
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or non-overlapping CIs suggest that random error is an unlikely explanation for the
observed variation (Murad et al., 2014). Measures of Q and I2 were used to
statistically evaluate the true variance and proportion of real dispersion (Borenstein et
al., 2009).
The Q statistic tests the homogeneity of the overall effect size with a null
hypothesis that the underlying effect is the same across studies. Q is an approximate
chi-square distribution with degrees of freedom equal to the number of studies minus
one. Rejection of the null hypothesis (p<.05) suggests that the effect size distribution
is heterogeneous and the variability is larger than what would be expected from
random error; variability and most likely attributable to study characteristics or
moderating variables. If the Q statistic is less than critical it suggests that the observed
variance does not exceed what would be expected from sampling error alone.
However, there are limitations to the Q statistic. Power can be low with small
samples and may miss the effects of study-level error (Lipsey & Wilson, 2001); in
consideration of Q’s limitations, P-values <.10 were considered significant to justify
moderator analyses. Q is a standardized measure and was computed as (Borenstein et
al., 2009):
𝑄 = ∑𝑘𝑖−𝐼 𝑊𝑖 (𝑌𝑖 − 𝑀)2,
where Wi is the study weight, Yi is the study effect size, and M is the overall effect
size.
The second statistical test used I2 where:
𝐼2 = (

𝑄 − 𝑑𝑓
) × 100%.
𝑄
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I2 is a measure of the magnitude of variability as opposed to a measure of statistical
significance like the Q statistic (Murad et al., 2014). I2 is a measure of the real
dispersion due to heterogeneity over random error alone (Higgins & Green, 2008), or
the ratio of excess dispersion to total dispersion (Borenstein et al., 2009). When I2 is
close to 0%, it is likely that observed variability between point estimates is due to
random error. The further I2 moves from 0, the more likely that variability is
explained by systematic differences requiring subgroup or moderator analyses.
Interpretation of I2 needs to consider not only magnitude and direction of effects, but
also the Q statistic and CIs for I2. Guidelines to interpret I2 vary, but rough guidelines
were used (Higgins et al., 2003):
1. 25%=low heterogeneity
2. 50%= moderate heterogeneity
3. 75% =high heterogeneity.
Statistical Tests of Moderators
Four design variables were specified as moderators a priori based on previous
work from Johnson et al., 2008: 1) outcome measure (count-level vs. dichotomous), 2)
comparison condition (non HIV-related vs. HIV-related vs. waitlist), 3) and
intervention time span (≤1 month vs. >1 month) and retention rate (better in
comparison vs. equal or intervention). Hypotheses specified that count-level
measures, non-HIV-related controls, interventions with shorter time spans, and
interventions with better retention in the treatment group would yield stronger effects
across all studies. In addition to a priori variables, participant characteristics and
study characteristics were analyzed as potential moderators for exploratory purposes.
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Variables tested for moderator analysis were categorical and continuous
variables and required different statistical tests. Categorical variables were tested
using the analog to analysis of variance (ANOVA). Continuous variables were tested
using weighted meta-regression analysis. Subgroup analyses used mixed-effects
models which use a fixed effect model across subgroups and a random effects model
within subgroup (Borenstein et al., 2009). The analog to ANOVA separates the total
homogeneity (Q) into between-group variance and within-group variance. Subgroup
analyses were computed by the general analog ANOVA given by:
𝑘

𝑄𝑤 = ∑ 𝑤𝑖 (𝐸𝑆𝑖 − 𝑀𝑗 )2
𝑖=1

where Qw is the pooled group (within) variance and QB is the between groups
variance:
𝑄𝐵 = ∑𝑘𝑖=1 𝑤𝑗 𝑀𝑗2 −

(Σ𝑗 𝑀𝑗 )2
Σ𝑤𝑗

.

𝑤𝑗 is equal to the sum of weights for each subgroup, 𝑀𝑗 refers to the weighted
1

mean effect size for each subgroup, 𝑤𝑖 is equal to the study weight (𝑆𝐸2 ), 𝐸𝑆𝑖 refers to
the study effect size, M is the summary effect, k is the number of studies (effect sizes)
and j refers to the number of groups (Borenstein et al., 2009; Lipsey & Wilson, 2001).
Continuous moderators were tested using the method of moments for metaregression analyses. Meta-regression assesses heterogeneity by developing regression
models with independent variables that represent individual study characteristics and
the dependent variable is the effect size (Borenstein et al., 2009; Murad et al., 2014).
Comparable to the analog ANOVA, variables were first assessed by a Q test; Q was
separated into variability accounted for by the: 1) regression equation (QR), and 2) the
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residual variance (QB) (Borenstein, 2009). True variance was explained by R2 given
by:
2
𝑇𝑢𝑛𝑒𝑥𝑝𝑙𝑎𝑖𝑛𝑒𝑑
𝑅 = 1 −(
)
2
𝑇𝑡𝑜𝑡𝑎𝑙
2

where R2 is the variance of true effect sizes across studies and T2 is Tau-squared.
(Borenstein et al., 2009).
Outliers and Sensitivity Analysis
Outlier analysis was performed to identify any study effect sizes that were extreme
and could distort the mean effect size or variance. The forest plot was visually
analyzed to identify extreme observations or very large sample sizes. Potential
outliers were then checked for data entry errors by performing a secondary review of
the manuscript and a second data extraction. Outliers found to be three standard
deviations from the mean (z=>3.0) were tested using sensitivity analysis where the
meta-analysis was run with outliers removed and compared to the original metaanalysis. Sensitivity analysis was also performed using a “one study removed”
analysis where the meta-analysis was run with all studies except the first, then all
studies except the second, and then the third, until all studies were run (Borenstein et
al., 2009). Forest plots were produced to plot effect sizes as each study was added and
their 95% CIs. Plots were visually examined to detect any shift in the effect sizes.
Studies found to be problematic were excluded and the meta-analysis was re-run to
compare results.
Publication Bias
Publication bias addresses the larger research issue that not all completed trials
are published. Trials accepted for publications are more likely to report large
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treatment effects than studies reporting modest or null effects (Dickersin & Min, 1993;
Borenstein et al., 2009). This publication bias can overestimate the treatment effect.
Every meta-analysis is vulnerable to publication bias and requires a combination of
methods to detect the impact of bias on the overall effect size. This review included
only peer-reviewed published articles as a method of quality control to ensure review
of the highest quality evidence. Therefore, this review may have a high risk of the
“file drawer” problem (Rosenthal, 1979) where the effect size is overestimated due to
studies with lower effect sizes being excluded. However, publication bias is thought
to be less likely in fields of public health importance such as HIV prevention because
results with small samples, small effects, or insignificant results are often published
(Marsh et al., 2001).
To test for publication bias and study its impact, six tests were conducted: 1)
the funnel plot, 2) Egger’s regression index, 3) Duval and Tweedie’s trim and fill test,
4) Rosenthal’s fail-safe N, 5) Orwin’s adapted version of Rosenthal’s fail-safe N, and
6) cumulative meta-analysis based on trial standard error. Additionally, trials were
coded as yes/no to indicate statistically significant positive effects.
Funnel Plot
The funnel plot was examined first. The funnel plot is a scatterplot that plots
the intervention effect size against the standard error or other measure of study
precision (i.e. sample size). Funnel plots allow for a quick visual display of
symmetry. Effect sizes were plotted on the X-axis and standard errors were plotted on
a reverse scale on the Y-axis. In the absence of publication bias, the scatter plot looks
like an inverted, symmetrical funnel. Typically, large studies (or studies with smaller
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standard errors) cluster towards the top of the graph and around the mean effect size
(Borenstein et al., 2009; Higgins & Green, 2008). Smaller studies appear towards the
bottom part of the graph and are often widely dispersed and fall to the right and left of
the mean. When an asymmetrical pattern appears with gaps on the left or right of the
mean, it suggests the presence of publication bias. The asymmetrical shape can
suggest that smaller studies were more likely to be included if they have larger than
average effects. These studies most likely met criterion for statistical significance and
were favored in publication over smaller studies with moderate results.
Visual interpretation of symmetry can help detect a relationship between
sample size and effect size, but it does not explain the relationship (Gleser & Olkin,
1996; Duval & Tweedie, 2000; Pham et al., 2000). For example, the studies may
represent a biased sample of smaller studies, or it is possible that the observed larger
effect size is truly larger in these studies due to study quality. Additional tests were
conducted to study “small study effects” and examine if small-study effects are caused
by methodological quality, true heterogeneity, study artifacts, or chance (Higgins &
Green, 2008; Egger 1997a).
Egger’s Test of the Intercept
Egger’s test of the intercept was conducted to yield a quantitative estimate of
the amount of bias observed in the funnel plot. Egger’s test is calculated by regressing
the standardized effect (i.e., the effect size divided by standard error) on the inverse of
the standard error (i.e., precision estimate). For this equation, the size of the treatment
effect is captured by the slope of the regression line (B1) and bias is captured by the
intercept (B0) (Borenstein et al., 2009). Studies with higher standard errors produce
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precision estimates closer to zero whereas studies with lower estimates of standard
error produce precision estimates further from zero, suggesting studies with more
robust sample sizes. Bias is detected by a regression line that does not approach the
intercept of origin.
Duval and Tweedie's Trim and Fill
Duval and Tweedie’s Trim and Fill method was used to impute studies that
were indicated as missing from the funnel plot (Duval & Tweedie, 2000). This
analysis was used to determine where the studies were missing on the plot, impute
their estimated values to the analysis, and then re-compute the combined effect
(Borenstein et al, 2009). The trim and fill method is an iterative procedure to remove,
or trim, extremely small studies from the right side of the plot while re-computing the
overall effect size with each iteration. Iterations continue until a symmetric funnel
plot is achieved for the revised effect size. Trimming reduces variance of effects and
shrinks confidence intervals. To compensate, the original studies are added (i.e.,
filled) back into the analysis, imputing a mirror image for each. A funnel plot was
produced that included both the original and imputed studies to visually examine any
effect size shift when imputed studies are included. The Trim and Fill method is very
sensitive to outlier studies, and has strong assumptions about reasons for the missing
data.
Rosenthal’s fail-safe N and Orwin’s adapted version of the fail-safe N
Rosenthal’s fail-safe N and Orwin’s adapted version of the fail-safe N were
conducted to assess the magnitude of the effect of publication bias and account for the
file-drawer problem (Rosenthal, 1979; Begg & Mazumdar, 1994). Rosenthal’s
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method computes the number of studies required to nullify the effect. When this
number is relatively small, publication bias is a potential threat. If this number if
large, it suggests the intervention effect is not nil. Rosenthal’s method needs to be
interpreted with caution because it assumes that the effect in the missing studies is nil,
as opposed to the effect of these studies being in the opposite direction, therefore the
true number of studies required to nullify the effect may be smaller than the calculated
fail-safe N. Additionally, the fail-safe N is a test based on statistical significance and
does not account for clinical significance. This study calculated the fail-safe N using
the modern practice of computing a summary effect, combining the effect sizes, and
then computing a p-value for the combined effect sizes. To address limitations of the
fail-safe N, Orwin’s fail-safe N was calculated and treated as a more reliable measure
of the number of studies needed to nullify the effect (Orwin, 1983). Orwin’s fail-safe
N differs from Rosenthal’s because it determines the number of studies using a
predetermined effect size set by the researcher, rather than an arbitrary p-value. This
allows the researcher to estimate how many missing studies are needed to bring the
overall effect size down before the overall effect would be trivial. In this study, the
criterion odds ratio that defined a trivial effect was set as 1.0 and the missing study
mean odds ratio was assumed to be 1.5.
Cumulative Meta-Analysis by Standard Error
Publication bias is assumed to be related to smaller studies or small-study
effects. The effect of study size was also examined using a cumulative meta-analysis.
This procedure is generally used to display shifts in the cumulative weight of the
evidence over time, but may also be used to further investigate impact of
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publication bias or small-study effects (Borenstein, Higgins, Rothstein, & Hedges,
2015). To use this procedure for publication bias, trials are sorted by precision, or
their standard error, in order of the most precise to least precise (i.e. smallest standard
errors to largest standard errors). Larger standard errors roughly correspond to smaller
sample size and less precision, so if the odds ratio does not shift with the addition of
the smaller studies, then there is no evidence to suggest publication bias related to
small-study effects. After trials were added from smallest to largest standard error,
cumulative meta-analysis was performed as each new study was added. Forest plots
were produced to display cumulative effect sizes with each new study. Visual
examination was performed to detect any shift in overall effect size when the smaller
trials (i.e. larger standard errors or less precise) were added. There is valid concern for
bias if the point estimate shifts with the addition of smaller trials, or trials with less
precision.
Missing data
For this study, missing data was related to reporting bias and refers to data
needed to calculate effect sizes for positive or negative effects in studies otherwise
eligible for review. Missing data can also refer missing values specific to covariates
used for subgroup analyses or meta-regressions. Effect sizes were calculated from
descriptive statistics when possible (e.g. sample size for intervention and comparison
groups, means, standard deviations, proportions). When descriptive statistics were not
available, values were converted from standard errors, t, F, exact p-values, or 95%
confidence intervals as appropriate (Higgins & Green, 2008). When data were not
available for effect size calculation, requests for descriptive data were sent to study
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authors. When study authors did not respond, requests were sent to authors of
previous meta-analyses who may have previously retrieved missing data from study
authors (e.g. CDC’s Prevention Research Synthesis Team). If study authors did not
respond, and effect sizes could not be accurately calculated, studies were excluded
from meta-analysis rather than performing imputation. Case analysis was used for
moderator data. Data were not imputed for moderator analyses, and studies with
missing data were excluded.

46

CHAPTER 5: RESULTS
Search Results
The search process is summarized in Figure 1. The search retrieved 4,147
records from electronic databases as potentially relevant citations: PubMed (1,208),
PsycINFO (1,807), EMBASE (766), CINAHL (245), and CENTRAL (121). Deduplication resulted in 3,059 records. Seven additional records were found through
hand searches resulting in 3,066 records for review. Manual review of record titles
resulted in 233 records deemed to be potentially relevant. Manual review of record
abstracts resulted in 108 records potentially eligible for inclusion and these
manuscripts were retrieved. After manual review of full text, 40 records were
excluded because they did not meet eligibility criteria. Sixty-eight manuscripts were
retained for full review by two coders.
During coding, the protocol was revised to add additional exclusions to
eligibility. Full review with new protocol exclusions resulted in thirty manuscripts
excluded due to having 100% HIV-positive MSM (k=16), not reporting a behavioral
outcome (k=5), not being specifically designed for MSM (k=2), or not having an
independent comparison group (k=7).

A total of 38 records were selected for

inclusion and effect size data were examined. Eight records were identified as eligible
for inclusion, but missing essential data. All eight authors were contacted and
missing data were requested. Three authors responded and provided data to calculate
an effect size for the specified primary outcome, and a previous meta-analysis
supplied effect size data for one trial. Four trials were excluded due to missing data
resulting in a final sample size of 34 trials (Table 1)
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Figure 1
Search and Retrieval Process Results

Description of Trials
An overview of trials are summarized in Table 1. Descriptive characteristics
are summarized in Table 2. A total of 17,872 participants were enrolled at baseline
across 34 trials (median sample size=328, range=50-4,295). Across all trials, a
median of 66 percent of participants were white (M=50.8, SD=35.8). A median of
nine percent of participants were black (M=29.5, SD=39.0), and 11 percent were
Latino (M=17.0, SD=25.3). Mean age was 33.3 (SD=5.4, median=34) years with a
mean range of 21.3-42.8 years. A median of 31 percent were high school graduates or
less, and a median of 15 percent were HIV-positive. Across 34 trials, only nine (26.4
percent) focused specifically on minority racial or ethnic groups (6=black,
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2=Hispanic/Latino, 1=Asian), four (11.8 percent) focused specifically on young adult
MSM, and 6 (17.6 percent) focused specifically on substance-using MSM. No studies
specifically focused on male sex workers, and only one study focused on men who
have sex with men and women (MSMW). A median of 74 percent of participants
reported any substance use and 42 percent reported mental health distress or history of
victimization. Most participants self-identified as gay or bisexual (median=98
percent). The majority of trials were conducted in the Western region of the U.S.
(k=16), 11 trials were conducted in the Northeast, five trials were conducted in the
Midwest, five were conducted in the South, and four recruited national samples using
the internet or telephone. Four trials had multiple trial sites in more than one U.S.
region. The most frequently reported trial sites were in cities with higher proportions
of MSM such as New York City, San Francisco, Los Angeles, and Seattle.
Eighteen trials (52.9 percent) contributed count-level primary outcomes and 16
(47.0 percent) contributed dichotomous outcomes as primary outcomes. Most trials
were either group-level interventions (k=17) or individual-level interventions (k=14).
Three interventions were community-level interventions. Median intervention time
span was 3 weeks (range 1-288 weeks) with a median of 4 sessions (range:1-48) and
median of 8 hours (range: 1-96). The majority of trials used an HIV-related
comparison group (k=17), seven used a non-HIV related comparison group, and 10
used a wait-list comparison group. More trials reported ≥80 percent overall retention
rates (k=19) than <80 percent retention (k=14). One study did not clearly report
retention rates and was excluded from retention analysis. Of trials that reported
retention rates by experimental condition (k=30), most trials (k=19 or 55.8 percent)
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reported equal or about equal retention rates, 10 trials reported better retention in the
comparison group, and no trials reported better retention in the intervention group.
Intervention content varied across trials. The majority of trials reported
intervention content that included the development of individualized risk reduction
plans (k=27). About 68 percent of trials (k=23) reported intervention content that
focused on increasing sexual communication, 58.8 percent (k=20) reported content
focused on increasing skills, and 41.1 percent (k=14) reported intervention content
focused on the impact of stigma or discrimination. Nine trials reported having
multiple behavioral outcomes of interest other than sexual risk reduction. Six focused
on additional outcomes of substance use reduction and three focused on increasing
HIV testing. Of these trials, six or 66.6 percent were conducted after the last review in
2007.
About half of trials (k=21, 62 percent) reported statistically significantly
different findings (P<.05) between experimental conditions on at least one relevant
outcome at last follow-up assessment. Eleven of 34 trials were found to be previously
classified as Evidence-Based Interventions (EBI) by CDC PRS and listed in the
Compendium (CDC, 2014b). Of the remaining 23 trials, 10 were classified as Positive
Non-EBIs, seven were Rigorous Non-EBIs, and six were Other Non-EBIs.
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Table 1
Overview of Included Trials
Publication

Year

CarballoDieguez et al.

2005

Carpenter et
al.
Choi et al.

2010

1995

Participants at
Baseline
180 Latino MSM
in
New York City
112 MSM aged
18-39 recruited
online
329 Asian Pacific
Islander MSM in
San Francisco
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2014

326 substanceusing MSM in
San Francisco

Dilley et al.

2002

305 HIV-negative
MSM in San
Francisco

Dilley et al.

2007

248 HIV-negative
MSM in San
Francisco

Eaton et al.

2011

149 HIV-negative
MSM in Atlanta

Coffin et al.

Intervention
Description

Level

8 weekly twohour sessions

GLI

Web-based skills
training, 1 twohour session
1 three-hour safer
sex skills training
group
1 one-hour
session of PCC
1 one-hour
session of PCC
with
paraprofessional
counselor
1 one-hour
session of PCC,
sexual diary
1 one-hour
session with peer
counselors to
address
serosorting risks

ILI

GLI

ILI

Effect
Measure*
No. UAI
events*, %
UAI

Control
Group

Follow-Up

Quality
Rating

Wait-list

12 months

Other NonEBI

No. UAI
events

Non-HIV
related

3 months

Positive
Non-EBI

Wait-list

3 months

EBI

HIV-related

6 months

Rigorous
Non-EBI

% UAI*,
No. male
partners
No. UAI
events*, No.
male
partners

ILI

No. UAI
events

HIV-related

12 months

EBI

ILI

% UAI

HIV-related

12 months

Rigorous
Non-EBI

ILI

No. male
partners

HIV-related

3 months

EBI

Year

Participants at
Baseline

Harawa et al.

2013

437 black MSMW
in Los Angeles

HightowWeidman et
al.

2012

50 young black
MSM in North
Carolina

Hirshfield et
al.

2012

3092 MSM
recruited online

Kegeles et al.

1996

300 young MSM
in Oregon

1989

104 HIV-negative
MSM in midsized city

Twelve 90-minute
weekly CBT
group sessions

GLI

Kelly et al.

1991

659 MSM in
Mississippi and
Louisiana

POL peer-led
community
intervention

CLI

Kelly et al.

1997

442 MSM in 8 US
cities

POL peer-led
community
intervention

CLI

Koblin et al.

2012

283 black MSM
in New York City

5 two-hour risk
reduction sessions
with meal prep

GLI
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Publication

Kelly et al.

Intervention
Description
MAALES 6 twohour small group
sessions
Four 30-minute
weekly sessions
by website
brief HIV
prevention video
or webpage
Peer-led outreach,
small groups, and
media campaign

Level

Effect
Measure

Control
Group

Follow-Up

Quality
Rating

GLI

No. UAI
events

HIV-related

6 months

EBI

ILI

No. male
partners*, %
UAI

HIV-related

3 months

Other NonEBI

ILI

% UAI
events

HIV-related

2 months

Positive
Non-EBI

CLI

% UAI
events

Wait-list

12 months

EBI

Wait-list

4 months

Positive
Non-EBI

Non-HIV
related

12 months

EBI

HIV-related

12 months

EBI

Non HIVrelated

3 months

Rigorous
Non-EBI

No. UAI
events*, %
condom use,
No. partners
% UAI
events*, %
condom use,
No. male
partners
No. UAI
events*, %
UAI; No.
male
partners
% UAI
events

Publication

Year

Participants at
Baseline

EXPLORE

2004

4295 MSM in six
US cities

2013

515 substanceusing MSM in
South Florida

2013

400 HIV-negative
MSM in San
Francisco,
Atlanta, and
Boston

2010

1686 substance
using MSM in 4
US cities

Menza et al.

2010

127 MSM who
use
methamphetamine
in Seattle

Mustanski et
al.

2013

102 young MSM
in Chicago

Kurtz et al.
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Lui et al.

Mansergh et
al.

Intervention
Description
10 counseling
sessions with 3month booster
session for 4 years
4 two-hour small
group weekly
sessions about
substance use and
sexual risk
PrEP, HIV
testing, risk
reduction
counseling every
3 months
6 two-hour CBT
group sessions
focused on
substance use and
sexual risk
12 weeks of biweekly
contingency
management
3 two-hour
sessions of KIU!
online program
focused on HIV
testing and sexual
risk

Level

Effect
Measure

Control
Group

Follow-Up

Quality
Rating

ILI

% UAI
events

HIV-related

48 months

EBI

GLI

No. UAI
events*, No.
male
partners

HIV-related

12 months

Rigorous
Non-EBI

ILI

% UAI
events

Wait-list

24 months

Other NonEBI

GLI

% UAI
events

Non HIVrelated

12 months

Rigorous
Non-EBI

ILI

% UAI
events*, No.
male
partners

Non HIVrelated

6 months

Rigorous
Non-EBI

ILI

No. UAI
events

HIV-related

3 months

Positive
Non-EBI

Publication

O’Donnell et
al.

Parsons et al.

Participants at
Baseline

2014

370 Latino MSM
in New York City

2014

143 substance
using young
MSM in New
York City

1996

318 HIV-negative
African-American
MSM in San
Francisco

2001

89 MSM in
Seattle

2007

319 MSM in
Seattle and
Portland
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Year

Peterson et al.

Picciano et al.

Picciano et al.

Intervention
Description
Adaptation of
VOICES/VOCES
(1 hour video)
into No
Excuses/Sin
Buscar Excuses
4 sessions of MI
delivered over 12
weeks focused on
substance use and
sexual risk
reduction
1 group or 3
three-hour weekly
small groups
using CBT selfmanagement
training
Single session 90minute telephonebased brief
counseling using
MI
Three 90-minute
sessions of MET
delivered by
telephone over 6
weeks

Level

Effect
Measure

Control
Group

Follow-Up

Quality
Rating

GLI

No. UAI
events*, %
condom use

HIV-related

3 months

EBI

LI

No. UAI
events

HIV-related

12 months

EBI

GLI

% UAI
events

Wait-list

18 months

Positive
Non-EBI

ILI

No. UAI
events*, No.
male
partners

Wait-list

2 months

Rigorous
Non-EBI

ILI

No. male
sex partners

HIV-related

10 months

Other NonEBI
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Publication

Year

Participants at
Baseline

Roffman et
al.

1997

548 MSM
recruited by
telephone

Roffman et
al.

1998

159 MSM in
Seattle

Simon Rosser
et al.

2002

422 MSM in a
Midwestern city

2005

162
methamphetamine
dependent MSM
in Los Angeles

Stall et al.

1998

456 MSM in
substance use
treatment in San
Francisco

Tobin et al.

2013

188 AfricanAmerican MSM
in Baltimore

Shoptaw et
al.

Intervention
Description
14 weekly 90minute group
CBT focused on
relapse prevention
by telephone
17weekly sessions
of group CBT
counseling
focused on relapse
prevention
2-day
comprehensive
human sexuality
seminar
16 weeks of triweekly 90-minute
culturally tailored
group CBT
16 unstructured
weekly 3-hour
treatment groups
focused on coping
skills
6 bi-weekly 2hour culturally
tailored group
modules plus one
individual session

Control
Group

Follow-Up

Quality
Rating

Wait-list

3 months

Positive
Non-EBI

GLI

No. UAI
events*, No.
male
partners

Wait-list

1 months

Positive
Non-EBI

GLI

% UAI
events

HIV-related

12 months

Positive
Non-EBI

GLI

No. UAI
events*, %
UAI

Non HIVrelated

12 months

Other NonEBI

GLI

% UAI
events

Non HIVrelated

15 months

Other NonEBI

GLI

% UAI
events

HIV-related

3 months

Positive
Non-EBI

Level

GLI

Effect
Measure
% UAI
events*, No.
UAI events,
No. male
partners

Publication

Year

Participants at
Baseline

Valdiserri et
al.

1989

584 MSM in
Pittsburgh

2009

338 HIV-negative
black MSM in
New York City

Wilton et al.

Intervention
Description
Small group
lecture plus skills
training for safer
sex negotiation
3MV 6 three-hour
sessions delivered
over 3 days as a
weekend retreat

Level

Effect
Measure

Control
Group

Follow-Up

Quality
Rating

GLI

No. male
sex partners

HIV-related

12 months

Positive
Non-EBI

GLI

No. UAI
events*, No.
male
partners

Wait-list

6 months

EBI
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Notes: *effect measure extracted for meta-analysis based on primary outcome or meta-analysis protocol
No.=number
%=percent
UAI=unprotected anal intercourse
MSM=men who have sex with men
MSMW=men who have sex with men and women
ILI=individual-level intervention
GLI=group-level intervention
CLI=community level intervention
EBI=evidence-based intervention
PCC=personalized cognitive counseling
MAALES=Men of African American Legacy Empowering Self
CBT=cognitive behavioral therapy
POL=Popular Opinion Leader
PrEP=pre-exposure prophylaxis
KIU!=Keep It Up!
MI=motivational interviewing
MET=motivational enhancement therapy
3MV=Many Men Many Voices.

Table 2
General Characteristics of Trials
Conducted Pre or Post ART
Pre-ART
Post-ART
MSM Subgroup
Young MSM
Racial/ethnic minority MSM
Substance-using MSM
Other or none specified
Region
Northeast
South
Midwest
West
National
Sample Characteristics
Median % black
Median % Latino
Median % white
Median % gay or bisexual
Median % HIV-positive
Median % high school or less
Median % mental health
Median age
Intervention Level
Individual
Group
Community
Comparison Group
Wait-list
HIV-related
Non HIV-related
Outcomes
Count-level*
Dichotomous*
Multiple outcomes reported
P<.05 result reported
Retention
>80% overall retention
Better in comparison condition
Better in intervention condition
About equal
Follow-Up Assessment
<3 months
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k (34)

Percent

11
23

32.3
67.6

4
9
6
15

11.8
26.5
17.6
44.1

11
5
5
16
4

32.3
14.7
14.7
47.0
6.8

29
29
34
20
30
25
5
34

9
11
66
98
15
31
42
34

14
17
3

41.1
50.0
8.8

10
17
7

29.4
50.0
20.6

18
16
9
21

52.9
47.0
26.5
61.7

19
11
0
19

55.9
32.3
0
55.9

12

35.2

Mean

SD

29.5
17.0
50.8
94.5
19.5
35.4
56.5
33.3

39.0
25.3
35.8
7.6
22.0
19.6
25.8
5.4

Table 2
General Characteristics of Trials
≥3 months
Intervention Dose
Median time span in weeks
Median total time in hours
Median # of sessions
Intervention Characteristics
Pilot tested
Conducted in MSM setting
Delivered by peers
Focus on sexual communication
Focus on skills building
Focus on individual plans
Focus on stigma
Use of technology
Evidence Level
Evidence-Based Intervention
Positive Non-EBI
Rigorous Non-EBI
Other Non-EBI

k (34)
22

Percent
64.7

Mean

SD

33
28
33

3
8
4

14.9
12.9
7.3

49.6
21.3
10.1

19
6
6
23
18
27
13
8

55.8
17.6
17.6
67.6
52.9
79.4
38.2
23.5

11
10
7
6

32.3
29.4
20.6
17.6

Notes: * outcome used in meta-analysis as primary outcome

Overall Meta-Analysis
Meta-analysis was conducted using data extracted from all 34 studies. Countlevel outcomes were used in 18 (52.9 percent) trials and dichotomous outcomes were
used in 16 (47.1 percent) trials. Effect sizes resulted from a total of 13,272
participants. Figure 2 displays the descriptive data, ORs, confidence intervals, and
outcome measures from each trial. Trials were sorted in descending order by year.
Effect sizes ranged from OR=0.431 to OR=1.343. Under the random effects model the
mean effect size was OR =0.859 (95% CI [0.790, 0.933]). This result was
significantly different than zero (p<.001). The fixed effects model yielded a
statistically significant result consistent with random effects (OR=.865, 95% CI
[0.815, 0.919], p<.001). Test of the Q statistic indicated little heterogeneity and was

58

not significant (Q[33]=39.35, p =.207). I2 was low indicating relatively little
heterogeneity (I2=16.14).
Cumulative Meta-Analysis
Cumulative meta-analysis was conducted on all 34 studies sorting by
publication year from earliest to latest (Figure 3). Effect size shrinkage was
determined by calculating the percent change from the first cumulative effect size that
became significant (third row: Kelly, 1991) to the last row. A gradual effect size
shrinkage of 19.5 percent was observed from 1991 (OR=.719) to 2014 (OR=.859).
The forest plot reveals the largest effect size shift to occur after the inclusion of
EXPLORE in 2004 from .720 (95% CI [0.619, 0.838]) to .777 (95% CI [0.688,
0.878]) resulting in a relative change over 1.0. After EXPLORE, the cumulative effect
size stabilized and confidence intervals narrowed. The effect size moved closer to the
null value of 1.0 with the addition of each new trial. Results warrant statistical
analysis of year as a covariate in meta-regression analyses.
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Figure 2
Overall Meta-Analysis Results

Effect Sizes of Behavioral Interventions for US MSM, 1988-2014
Study name

Outcome

Statistics for each study
Odds
ratio
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Parsons, 2014
Coffin, 2014
Odonnell, 2014
Mutanski, 2013
Tobin, 2013
Kurtz, 2013
Harawa, 2012
Lui, 2013
Hightow-Weidman, 2012
Hirshfield, 2012
Koblin, 2012
Eaton, 2011
Carpenter, 2010
Menza, 2010
Mansergh, 2010
Wilton, 2009
Dilley, 2007
Picciano, 2007
Shoptaw, 2005
Carballo-Dieguez, 2005
EXPLORE, 2004
Dilley, 2002
Simon Rosser, 2002
Picciano, 2001
Roffman, 1998
Stall, 1998
Roffman, 1997
Kelly, 1997
Kegeles, 1996
Choi, 1996
Peterson, 1996
Kelly, 1991
Kelly, 1989
Valdiserri, 1989

% UAI events
# UAI events
# UAI events
# UAI events
% UAI events
# UAI events
# UAI events
% UAI events
# sex partners
% UAI events
% UAI events
# sex partners
# UAI events
% UAI events
% UAI events
# UAI events
# UAI events
# sex partners
# sex partners
# UAI events
% UAI events
% UAI events
% UAI events
# UAI events
# UAI events
% UAI events
% UAI events
# UAI events
% UAI events
% UAI events
% UAI events
% UAI events
# UAI events
# sex partners

0.473
0.978
1.000
0.624
0.738
0.817
0.946
1.212
0.688
1.082
1.343
0.477
0.717
0.933
1.089
0.634
0.937
0.938
1.016
1.223
0.860
0.431
0.523
0.740
1.089
1.327
0.563
0.630
0.649
0.777
1.119
0.625
0.528
0.900
0.859

Lower
limit

0.219
0.659
0.682
0.308
0.328
0.585
0.623
0.789
0.219
0.825
0.806
0.246
0.365
0.266
0.853
0.407
0.624
0.630
0.382
0.628
0.788
0.187
0.236
0.348
0.578
0.593
0.325
0.406
0.355
0.449
0.442
0.443
0.243
0.641
0.790

Upper
limit

1.021
1.449
1.466
1.265
1.660
1.141
1.435
1.861
2.161
1.418
2.239
0.924
1.408
3.269
1.391
0.987
1.409
1.397
2.702
2.382
0.938
0.993
1.158
1.576
2.052
2.973
0.976
0.979
1.188
1.347
2.832
0.883
1.149
1.263
0.933

Odds ratio and 95% CI
Z-Value

p-Value

-1.908
-0.113
0.000
-1.307
-0.734
-1.186
-0.262
0.880
-0.641
0.570
1.131
-2.195
-0.966
-0.108
0.683
-2.019
-0.311
-0.313
0.031
0.592
-3.401
-1.975
-1.597
-0.780
0.265
0.688
-2.045
-2.056
-1.402
-0.899
0.237
-2.668
-1.610
-0.610
-3.580

0.056
0.910
1.000
0.191
0.463
0.236
0.794
0.379
0.521
0.569
0.258
0.028
0.334
0.914
0.494
0.043
0.756
0.754
0.975
0.554
0.001
0.048
0.110
0.435
0.791
0.491
0.041
0.040
0.161
0.369
0.813
0.008
0.108
0.542
0.000
0.1

0.2

0.5

Fav ours interv ention

k=34, random effects model

1

2

5

Fav ours control

10

Figure 3
Cumulative Meta-Analysis Results

Cumulative Effect Sizes by Trial Year of Publication, 1988-2014
Study name

Outcome

Cumulativ e statistics
Point
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Kelly, 1989
Valdiserri, 1989
Kelly, 1991
Kegeles, 1996
Choi, 1996
Peterson, 1996
Roffman, 1997
Kelly, 1997
Roffman, 1998
Stall, 1998
Picciano, 2001
Dilley, 2002
Simon Rosser, 2002
EXPLORE, 2004
Shoptaw, 2005
Carballo-Dieguez, 2005
Dilley, 2007
Picciano, 2007
Wilton, 2009
Carpenter, 2010
Menza, 2010
Mansergh, 2010
Eaton, 2011
Hightow-Weidman, 2012
Hirshfield, 2012
Koblin, 2012
Mutanski, 2013
T obin, 2013
Kurtz, 2013
Harawa, 2012
Lui, 2013
Parsons, 2014
Coffin, 2014
Odonnell, 2014

# UAI events
# sex partners
% UAI events
% UAI events
% UAI events
% UAI events
% UAI events
# UAI events
# UAI events
% UAI events
# UAI events
% UAI events
% UAI events
% UAI events
# sex partners
# UAI events
# UAI events
# sex partners
# UAI events
# UAI events
% UAI events
% UAI events
# sex partners
# sex partners
% UAI events
% UAI events
# UAI events
% UAI events
# UAI events
# UAI events
% UAI events
% UAI events
# UAI events
# UAI events

0.528
0.777
0.719
0.718
0.726
0.740
0.718
0.704
0.725
0.743
0.743
0.729
0.720
0.777
0.793
0.797
0.815
0.832
0.817
0.828
0.828
0.831
0.815
0.818
0.833
0.843
0.838
0.839
0.840
0.846
0.855
0.846
0.853
0.859
0.859

Lower
limit

0.243
0.487
0.534
0.578
0.594
0.608
0.597
0.594
0.615
0.632
0.634
0.624
0.619
0.688
0.711
0.714
0.741
0.770
0.750
0.771
0.771
0.757
0.737
0.742
0.755
0.761
0.759
0.761
0.767
0.776
0.783
0.774
0.782
0.790
0.790

Upper
limit

1.149
1.239
0.966
0.893
0.888
0.901
0.864
0.835
0.855
0.873
0.870
0.851
0.838
0.878
0.883
0.891
0.897
0.899
0.890
0.889
0.889
0.913
0.902
0.901
0.919
0.933
0.926
0.924
0.920
0.922
0.933
0.926
0.929
0.933
0.933

Cumulativ e odds ratio (95% CI)
Z-Value

p-Value

-1.610
-1.059
-2.188
-2.981
-3.123
-3.002
-3.514
-4.036
-3.829
-3.614
-3.697
-3.999
-4.231
-4.062
-4.218
-3.998
-4.207
-4.679
-4.635
-5.222
-5.219
-3.884
-3.960
-4.077
-3.635
-3.307
-3.460
-3.558
-3.768
-3.803
-3.508
-3.637
-3.621
-3.580
-3.580

0.108
0.289
0.029
0.003
0.002
0.003
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.001
0.001
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.000
0.5

1
Fav ours interv ention

k=34, random effects model

2
Fav ours control

Publication Bias Analysis
Analysis of publication bias indicated a small amount of risk based on
observed asymmetry in the funnel plot (Figure 4). More studies are observed towards
the top of the graph, and less towards the bottom. Slightly more trials were observed
to the left of the mean effect size indicating there were a few trials that may be missing
from the right side of the mean effect size (OR>1.0) due to reporting bias. Statistical
analyses of potential publication bias suggests a small amount of bias.
Figure 4
Funnel Plot for Publication Bias
Funnel Plot of Standard Error by Log odds ratio
0.0

Standard Error

0.2

0.4

0.6

0.8
-2.0

-1.5

-1.0

-0.5

0.0

0.5

1.0

1.5

2.0

Log odds ratio

Rosenthal’s fail-safe N test required the addition of 143 missing trials to nullify
the effect, or 4.2 studies per every observed trial. Orwin’s N was more conservative,
but indicated that 101 missing studies would be needed to bring the effect size over a
mean odds ratio of 1.0. Both of these tests indicate minimal potential for publication
bias. Trim and fill analysis suggested the imputation of five studies which aligns
closely with our missing data procedures that resulted in 4 excluded studies. The
filled circles in Figure 4 represent imputed values on the right side. Trim and fill
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estimated the real effect size to be consistent with the observed effect size with OR =
.858 (95% CI [0.790, 0.933]) under the random effects model, and OR=.865 under the
fixed effects model (95% CI [0.814, 0.919]). Egger’s regression was not significant
(B = -0.35, t(32) = 1.19, 95% CI [-0.949, 0.247], p =0.120), indicating lack of
publication bias. Finally, a cumulative meta-analysis of precision was conducted
where trials were sorted by precision, and added in order of smallest to largest
standard error. Visual examination did not detect a shift in overall effect size when
the trials with larger standard errors (i.e. trials with smaller samples) were added,
indicating minimal publication bias or minimal small-study effects. Results are
presented in Figure 5. Synthesis of all publication bias analyses suggests this study
was subject to minimal publication bias, though there may be some trials missing.
Minimal bias results are consistent with literature cited previously that suggests
statistically insignificant, and small studies, are likely to published in the HIV
prevention literature.

63

Figure 5
Cumulative Effect Sizes by Precision

Cumulative Effect Sizes by Precision, 1988-2014
Study name

Outcome

Cumulativ e statistics
Point
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EXPLORE, 2004
Mansergh, 2010
Hirshfield, 2012
Kurtz, 2013
Valdiserri, 1989
Kelly, 1991
Odonnell, 2014
Coffin, 2014
Picciano, 2007
Dilley, 2007
Harawa, 2012
Lui, 2013
Kelly, 1997
Wilton, 2009
Koblin, 2012
Choi, 1996
Roffman, 1997
Kegeles, 1996
Roffman, 1998
Eaton, 2011
Carballo-Dieguez, 2005
Carpenter, 2010
Mutanski, 2013
Picciano, 2001
Parsons, 2014
Kelly, 1989
Simon Rosser, 2002
Stall, 1998
Tobin, 2013
Dilley, 2002
Peterson, 1996
Shoptaw, 2005
Hightow-Weidman, 2012
Menza, 2010

% UAI events
% UAI events
% UAI events
# UAI events
# sex partners
% UAI events
# UAI events
# UAI events
# sex partners
# UAI events
# UAI events
% UAI events
# UAI events
# UAI events
% UAI events
% UAI events
% UAI events
% UAI events
# UAI events
# sex partners
# UAI events
# UAI events
# UAI events
# UAI events
% UAI events
# UAI events
% UAI events
% UAI events
% UAI events
% UAI events
% UAI events
# sex partners
# sex partners
% UAI events

0.860
0.940
0.970
0.937
0.923
0.895
0.903
0.906
0.905
0.902
0.895
0.912
0.906
0.896
0.908
0.903
0.893
0.887
0.890
0.879
0.885
0.882
0.877
0.876
0.868
0.862
0.856
0.861
0.860
0.852
0.855
0.857
0.857
0.859
0.859

Lower
limit

0.788
0.751
0.810
0.812
0.824
0.781
0.799
0.812
0.821
0.827
0.832
0.841
0.829
0.816
0.824
0.824
0.812
0.807
0.813
0.799
0.805
0.805
0.801
0.802
0.793
0.787
0.782
0.787
0.788
0.779
0.782
0.786
0.787
0.790
0.790

Upper
limit

0.938
1.177
1.163
1.082
1.034
1.025
1.020
1.012
0.999
0.983
0.962
0.990
0.991
0.983
1.000
0.991
0.982
0.974
0.975
0.967
0.972
0.967
0.961
0.957
0.950
0.944
0.938
0.942
0.940
0.933
0.935
0.935
0.934
0.933
0.933

Cumulativ e odds ratio (95% CI)
Z-Value

p-Value

-3.401
-0.538
-0.326
-0.887
-1.389
-1.604
-1.637
-1.745
-1.980
-2.338
-2.995
-2.192
-2.147
-2.323
-1.969
-2.159
-2.333
-2.514
-2.498
-2.638
-2.546
-2.682
-2.828
-2.942
-3.066
-3.202
-3.337
-3.246
-3.336
-3.464
-3.450
-3.466
-3.537
-3.580
-3.580

0.001
0.591
0.744
0.375
0.165
0.109
0.102
0.081
0.048
0.019
0.003
0.028
0.032
0.020
0.049
0.031
0.020
0.012
0.012
0.008
0.011
0.007
0.005
0.003
0.002
0.001
0.001
0.001
0.001
0.001
0.001
0.001
0.000
0.000
0.000
0.5

1
Fav ours interv ention

k=34, random effects model

2
Fav ours control

Outlier Examination
Only one trial produced a z-score higher than 3.0 and was subject to outlier
examination. EXPLORE (Koblin et al., 2004) was the largest trial (N=4,295) with the
smallest standard error (0.04) and z-score of -3.401 (OR=.860, 95% CI [0.788,
0.938]). Meta-analysis was repeated without EXPLORE and results were compared.
Table 3 displays the mean effect sizes with all trials and then with EXPLORE
removed. EXPLORE was retained in the overall analysis because its exclusion did not
contribute to change in the overall result. EXPLORE was also retained due to its
important contribution to HIV prevention as a landmark trial enrolling the largest
group of MSM with the longest follow-up period. Sensitivity analysis using a “one
study removed” analysis was performed to confirm that no single study (including
EXPLORE) contributed to an observed shift in effect sizes. Forest plots produced
from a one-study-removed analysis showed little shift in effect sizes (Figure 6).
Table 3
Sensitivity Analysis
Analysis
All studies

k
34

EXPLORE
33
removed
Notes: *not significant

Model

OR

Fixed
Random
Fixed
Random

0.865
0.859
0.870
0.853
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95% CI
LCL
UCL
0.815
0.919
0.790
0.933
0.800
0.946
0.773
0.940

P

Q (df)

<.001
<.001
<.001
<.001

39.35 (33)*
39.32 (32)*

Figure 6
One Study Removed Outlier Analysis

One Study Removed, 1988-2014
Outcome

Study name

Statistics with study remov ed
Point
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# UAI events
# UAI events
% UAI events
# UAI events
# UAI events
% UAI events
# UAI events
% UAI events
% UAI events
% UAI events
# sex partners
# sex partners
% UAI events
# UAI events
% UAI events
# UAI events
# sex partners
# UAI events
# UAI events
# sex partners
% UAI events
% UAI events
% UAI events
# UAI events
# UAI events
% UAI events
# UAI events
% UAI events
% UAI events
% UAI events
% UAI events
% UAI events
# sex partners
# UAI events

Odonnell, 2014
Coffin, 2014
Parsons, 2014
Kurtz, 2013
Harawa, 2012
Lui, 2013
Mutanski, 2013
T obin, 2013
Hirshfield, 2012
Koblin, 2012
Hightow-Weidman, 2012
Eaton, 2011
Mansergh, 2010
Carpenter, 2010
Menza, 2010
Wilton, 2009
Picciano, 2007
Dilley, 2007
Carballo-Dieguez, 2005
Shoptaw, 2005
EXPLORE, 2004
Simon Rosser, 2002
Dilley, 2002
Picciano, 2001
Roffman, 1998
Stall, 1998
Kelly, 1997
Roffman, 1997
Choi, 1996
Kegeles, 1996
Peterson, 1996
Kelly, 1991
Valdiserri, 1989
Kelly, 1989

0.853
0.853
0.866
0.859
0.855
0.851
0.862
0.859
0.846
0.852
0.859
0.868
0.845
0.860
0.857
0.868
0.855
0.855
0.854
0.857
0.853
0.864
0.866
0.859
0.855
0.855
0.868
0.868
0.859
0.863
0.856
0.875
0.855
0.864
0.859

Lower
limit

0.782
0.783
0.798
0.787
0.784
0.784
0.792
0.789
0.779
0.786
0.789
0.802
0.778
0.790
0.787
0.799
0.783
0.784
0.785
0.787
0.773
0.795
0.799
0.789
0.785
0.786
0.799
0.800
0.789
0.793
0.786
0.807
0.783
0.795
0.790

Upper
limit

0.929
0.931
0.939
0.938
0.932
0.924
0.938
0.936
0.920
0.924
0.935
0.940
0.917
0.937
0.934
0.943
0.932
0.932
0.929
0.933
0.940
0.938
0.939
0.936
0.931
0.930
0.943
0.942
0.937
0.939
0.932
0.948
0.934
0.939
0.933

Odds ratio (95% CI) with study remov ed

Z-Value

p-Value

-3.621
-3.590
-3.478
-3.381
-3.551
-3.855
-3.445
-3.485
-3.915
-3.888
-3.505
-3.478
-4.039
-3.458
-3.537
-3.341
-3.544
-3.543
-3.674
-3.555
-3.201
-3.464
-3.505
-3.478
-3.616
-3.668
-3.339
-3.404
-3.449
-3.421
-3.582
-3.274
-3.492
-3.460
-3.580

0.000
0.000
0.001
0.001
0.000
0.000
0.001
0.000
0.000
0.000
0.000
0.001
0.000
0.001
0.000
0.001
0.000
0.000
0.000
0.000
0.001
0.001
0.000
0.001
0.000
0.000
0.001
0.001
0.001
0.001
0.000
0.001
0.000
0.001
0.000
0.5

1
Fav ours interv ention

k=34, random effects model

2
Fav ours control

Moderator Analysis
The presence of moderating effects was not indicated by a significant Q
statistic or an I2 statistic that suggested heterogeneity. However, both Q and I2 have
limitations in interpreting heterogeneity, and due to the relatively small number of
trials included, moderator analyses were conducted as planned. Effect sizes and
moderator analyses identified a priori are displayed first in Table 4, followed by other
moderator analyses using analog to ANOVA, and then meta-regressions. No variables
hypothesized a priori as moderators were found to be significant (i.e. effect size
measure, differential retention, intervention time span, and comparison group).
Two variables tested post-hoc were statistically significant at the p<.05 level in
analog to ANOVA tests. Peer-led interventions were found to be more effective than
non Peer-Led interventions (OR=0.676, 95% CI [0.569, 0.803], Q(1)=9.148, p=.002),
Larger effect sizes were found for community-level interventions [OR=0.631, 95% CI
[0.492, 0.808], Q(2)=6.879, p=.032), than individual or group-level interventions.
Post-hoc meta-regressions of continuous variables revealed four statistically
significant moderators (p<.05). The overall effect size decreased with year of
publication (QR=5.80(1), B=.012, 95% CI [0.002, 0.022], p=.016), (Figure 7)
supporting previous results from cumulative meta-analyses that showed declines in
effect size over time. Effect sizes were larger when trials had a higher proportion of
MSM under 30 or younger MSM (QR=16.02(1), B=.034, 95% CI [0.015, 0.055],
p<.001), (Figure 8) and when trials had lower representation of MSM with a high
school education or less (QR=4.49(1), B=.005, 95% CI [0.006, 0.009], p=.023) (Figure
9). Of trials that did not exclude HIV-positive persons, effect sizes were smaller
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among trials with more HIV-positive participants (QR=5.50(1), B=.005, 95% CI
[0.001, 0.008], p=.019) (Figure 10). HIV-status was further analyzed by creating a
dichotomous variable to indicate when trials had more than 20 percent HIV-positive
participants. Based on this analysis, trials with less HIV-positive participants were
observed to have larger effects (OR=.809, 95% CI [0.726, 0.902], Q(1)=4.58, p=.032).
Finally, 11 trials excluded HIV-positive participants in their eligibility criteria. In
subgroup analyses, trials that excluded HIV-positive MSM had larger effects
(OR=.765, 95% CI [0.640, 0.916], Q(2)=9.742, p=.008).
ANOVA analog also indicated trend level (p <.10) differences between
Evidence-Level [Q=6.869(3), p=.076]. Trials classified as highest-level evidence,
Evidence-Based Interventions (EBI), showed larger effect sizes (OR=.776, 95% CI
[0.682, 0.883]) than lower levels of evidence. Trials focusing on specific MSM
subpopulations suggested varying effects based on subpopulation [Q=6.271(3),
p=.099). Trials focused on young MSM (OR=.616, 95% CI [0.418, 0.907]) and trials
with no specific population (OR=.825, 95% CI [0.793, 0.913]) appeared to be more
effective than trials focusing on substance users or MSM of color. Finally, trials with
<80 percent overall retention appeared to be slightly more effective than trials with
higher retention (OR=.775, 95% CI [0.667, 0.901], Q(1)=2.809, p=.094).
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Table 4
Moderator Analyses
Variable

K

OR

SE

95% CI
LCL
UCL

P

Mean Effect Size
Fixed

34

0.865

0.026

0.815

0.919

.<001

Random

34

0.859

0.036

0.790

0.933

<.001

.666

Homogeneity

Q [33] = 39.350, p =.207

Comparison
Condition*
HIV-related

17

0.857

0.012

0.787

0.932

Non HIV-related

7

0.947

0.068

0.728

1.232

Wait-list

10

0.813

0.052

0.661

0.998

Count-level

16

0.859

0.028

0.742

0.993

Dichotomous

18

0.842

0.051

0.167

0.369

Control

10

0.857

0.017

0.794

0.926

Equal

24

0.846

0.114

0.745

0.961

≤1 month

20

0.847

0.022

0.754

0.952

>1 month

14

0.868

0.022

0.758

0.993

Effect Measure*
.835

Retention Better*
.861

Time Span*
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.792

Table 4
Moderator Analyses
Variable

K

OR

SE

95% CI
LCL
UCL

P

Pre or Post ART
Pre

11

0.866

0.004

0.812

0.968

Post

23

0.792

0.022

0.661

0.949

Young MSM

4

0.616

0.133

0.418

0.907

MSM of color

9

0.881

0.718

0.742

1.056

Substance Users

6

0.996

0.842

0.842

1.179

None

15

0.825

0.729

0.793

0.913

Northeast

7

0.887

0.056

0.703

1.118

West

13

0.859

0.039

0.729

1.013

South

4

0.749

0.041

0.605

0.927

Midwest

2

0.577

0.208

0.340

0.979

National

4

0.809

0.118

0.560

1.170

Multi-site

4

0.924

0.037

0.751

1.137

.273

MSM Subpopulation
.099

Region
.523

Intervention Level
Individual

14

0.872

0.019

0.795

0.981

Group

17

0.909

0.023

0.806

1.025
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.032

Table 4
Moderator Analyses
Variable
Community

K
3

95% CI
LCL
UCL

OR

SE

0.631

0.053

0.492

0.808

P

Multiple Outcomes
Yes

9

0.915

0.030

0.785

1.066

No

25

0.842

0.017

0.760

0.933

Yes

21

0.826

0.016

0.744

0.916

No

13

0.921

0.026

0.801

1.059

Yes

19

0.898

0.013

0.826

0.975

No

15

0.775

0.032

0.667

0.901

≤3 Months

11

0.841

0.038

0.709

0.998

>3 Months

23

0.864

0.015

0.782

0.955

Yes

7

0.676

0.033

0.569

0.803

No

27

0.901

0.012

0.840

0.968

23

0.838

0.013

0.764

0.919

.372

Significant Result
.217

≥80% Retention
.094

Follow-Up
Assessment
.796

Peer Delivery
.002

Sexual
Communication
Yes
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.228

Table 4
Moderator Analyses
Variable

95% CI
LCL
UCL

K

OR

SE

11

0.954

0.047

0.789

1.154

Yes

18

0.876

0.011

0.819

0.937

No

16

0.813

0.043

0.684

0.967

No

P

Skills Building

Individual Plans

.433

.118

Yes

27

0.829

0.017

0.749

0.917

No

7

0.965

0.030

0.821

1.133

Stigma

.997

Yes

13

0.854

0.019

0.791

0.922

No

21

0.854

0.025

0.754

0.967

Technology

.704

Yes

8

0.826

0.048

0.673

1.014

No

26

0.863

0.015

0.785

0.949

Evidence Level

.076

EBI

11

0.776

0.020

0.682

0.883

Positive

10

0.839

0.041

0.846

1.368

Rigorous

7

0.952

0.040

0.700

1.007

Other

6

1.076

0.064

0.784

1.157

72

Variable

K

QR

34

Age

B 95% CI
LCL
UCL

B

SE

5.08

0.012

0.005

0.002

0.022

.016

34

16.02

0.034

0.010

0.015

0.055

<.001

% Black

29

0.03

-0.000

-0.003

0.003

.864

% White

29

0.03

-0.000

0.001

-0.003

0.002

.854

% Latino

29

0.75

0.002

0.002

-0.002

0.005

.387

% Gay or
Bisexual

20

0.93

0.008

0.009

-0.009

0.025

.335

% HIV-positive

23

5.50

0.005

0.002

0.001

0.008

.019

25

4.49

0.005

0.002

0.006

0.009

.034

20

0.01

0.001

0.010

-0.018

0.021

.910

18

0.01

0.001

0.007

-0.013

0.014

.934

Study Year

P

Demographics

% High school
or less
Number of
Sessions
Number of Hours

*=moderators hypothesized a priori

73

0.001

Figure 7
Scatter Plot of Log Odds Ratio by Year Published
Regression of Log odds ratio on Year Published
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Figure 8
Scatter Plot of Log Odds Ratio by Age
Regression of Log odds ratio on Age
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Figure 9
Scatter Plot of Log Odds Ratio by Education Level
Regression of Log odds ratio on Education Level (% High School or Less)
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Figure 10
Scatter Plot of Log Odds Ratio by HIV Status
Regression of Log odds ratio on HIV Status (% HIV-Positive)
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CHAPTER 5: DISCUSSION
Summary of Findings
This study evaluated effects of 34 randomized controlled trials of HIV
behavioral interventions for 17,872 MSM conducted between 1989 and 2014.
Overall, behavioral interventions reduced the odds of sexual risk behavior by 14
percent (OR=.859, 95% CI [0.790, 0.933], p<.001). These findings show that
behavioral interventions are still somewhat effective to prevent HIV transmission
among MSM. However, the updated effect size was considerably smaller than the
magnitude of effects observed in earlier meta-analyses.
This study also examined effect size moderators, integrated interventions, and
cumulative effect sizes over time. Intervention effects were highly statistically
homogenous, and all moderators hypothesized a priori were insignificant. Post-hoc
analyses found eight variables (subpopulation, retention, peer delivery, evidence-level,
intervention-level, age, HIV status, education) to be statistically related to
effectiveness, but findings need to be interpreted with caution due to their exploratory
nature. Qualitative review identified nine trials as integrated interventions; six trials
included a primary outcome related to substance use and three included outcomes
related to HIV testing. Consistent with study hypotheses, most of these trials were
conducted after the last review in 2007.
Most notably, this study revealed an unexpected finding related to the
cumulative effect size over time. Cumulative meta-analysis revealed that intervention
effects gradually weakened over time. From 1991 to 2014, the magnitude of the effect
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size decreased by 19.5 percent (OR=.719-.859). Follow-up meta-regression analysis
using publication year as a moderator variable added statistical evidence for effect size
shrinkage over time. Reasons for effect size decline were not able to be explained due
to statistical homogeneity. However, several factors such as HIV prevention fatigue,
inclusion criteria, comparison condition, and underpowered trials may contribute to
effect size shrinkage.
Overall Meta-Analysis and Effect Size
This meta-analysis provides updated evidence that HIV behavioral
interventions still show significant overall effects to reduce sexual risk behavior
among US MSM. However, the current evidence is weaker than hypothesized.
Findings support current thinking that behavioral interventions are necessary, but no
longer sufficient for HIV prevention (Coates, 2013). To our knowledge, this metaanalysis is the most recent quantitative synthesis of behavioral interventions designed
for US MSM, and includes trials conducted up to the end of calendar year 2014.
Multiple tests were conducted to support the validity of its overall finding.
Publication bias analyses indicated little to no publication bias, and small study effects
were not shown to inject bias when effect sizes were plotted by precision. Iterative
sensitivity analyses did not reveal any significant outliers. These results combined
with previous meta-analyses provide good support for the continued funding of
behavioral intervention trials, especially when implemented as part of combination
prevention agendas.
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The observed 14 percent decrease in sexual risk behavior is modest, and
considerably smaller than the last meta-analysis. While a 14 percent decrease may
still confer some protection on an individual level, significant changes in HIV
epidemics require larger effect sizes maintained over time, and among more people
(Coates et al., 2008). More successful interventions have decreased the odds of risk
behavior by about 25 percent (Johnson et al., 2002). Even if HIV behavioral
interventions were to demonstrate greater reductions in risk behavior, it is unlikely that
they can avert large numbers of infections (IOM, 2001).
This study hypothesized that the updated effect size would be comparable to
previous meta-analyses, despite variations in study protocols. Previous meta-analyses
found behavioral interventions to decrease sexual risk behavior by about twice as
much (Herbst, et al., 2005; Johnson et al., 2002a; Johnson et al 2005; Johnson et al.,
2008). In the last meta-analysis, Johnson (2008) found interventions to decrease UAI
by 27 percent when compared to non-HIV related controls, and by 17 percent when
compared with HIV-related controls. While it is possible that this study’s scope was
too different to merit meaningful comparisons to other meta-analyses, it is clear that
effects have changed over time. Observed effect size shrinkage warrants additional
research including replication studies to examine if earlier trials (especially pre-ART)
are no longer comparably effective among current MSM populations (Higa et al.,
2013).
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Gradual Effect Size Shrinkage
Contrary to the hypothesis, this study found that the effect size was only about
half as large as expected. Further, cumulative meta-analysis showed that the effect
size gradually weakened over time, and has slowly moved closer to the null value of 1.
Visual results were supported by meta-regression results that revealed a linear
relationship between publication year and effect size; the overall effect size declined
with each new publication year (Figure 7). Reasons for effect size decline are not
known, but may be related to multiple factors including MSM subpopulation, HIV
prevention fatigue, comparison condition, and underpowered trials.
Cumulative meta-analysis (CMA) was used to accomplish the study objective
of displaying effect sizes over time. CMA addresses the impact of each new trial on
prior pooled results and assesses how robust meta-analytic results remain over time
(Trikalinos et al., 2004; Ioannidis, Contopoulous-Ioannidis & Lau, 1999). A
systematic review of over 1,500 CMAs conducted on healthcare interventions
discovered three main patterns of effect size change: early positive results became null
or negative over time; null or negative results became positive over time; or results
stabilized, but intervention research continued (Clarke, Brice, & Chalmers, 2014).
Studies demonstrating effect size shrinkage over time with CMA are not
uncommon, and CMA may be particularly important in fields where small trials
dominate the RCT literature (Bollen, Utterwaal, & Vaught, 2003; Hanson & Broom,
2005; Klein, Jacobs, & Reinecke, 2007; Zhang et al., 2010; Trikalinos et al., 2004).
Trikalonas et al. conducted a review of 100 meta-analyses of mental health
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randomized trials (N=99,303) to test how effect sizes changed over time. The authors
calculated the size and direction of the relative change in the cumulative effect size at
each calendar year. Relative changes were calculated by the formula: ORsubsequent
step/ORcurrent step.

Relative changes over 1 indicated shift favoring the comparison over

intervention group. They found that the magnitude of the effect size shifted
considerably from early positive results to null results, raising questions about how
effect size shrinkage in the mental health field may impact declining clinical
importance.
In this study, the most noticeable shift in effect size occurred with the inclusion
of EXPLORE in 2004 when the cumulative ES shifts from .720 to .777. Using
Trikalinos’s calculations, this shift equates to a relative change over 1 and a shift
unfavorable to the intervention group (Trikalonas et al., 2004). After 2005, the effect
size clearly stabilizes, showing gradual effect size shrinkage over time. The impact of
EXPLORE’s weight is the most likely explanation for the overall effect size shift;
EXPLORE is the largest behavioral trial to date (N=4,295, OR=0.86) and accounts for
the largest relative weight in this study (18.2). Generally, HIV prevention research is
dominated by smaller studies. Median sample size for this study was 328 and only
two trials in this study had samples over 1,000 participants. In addition to its
unusually large sample size, EXPLORE was also the only trial with a z-score >3.0.
Since sensitivity analyses did not show that EXPLORE exerted influence on the
overall effect size, it was included in the meta-analysis. While the weight of
EXPLORE may have contributed to some effect size shift, there are likely other
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important reasons that contribute more to effect size decline. In many cases of CMA,
there are limited data to fully understand effect size shift over time (Iaonnidis et al.,
1999).
To our knowledge, CMA has not been conducted to assess the robustness of
effect sizes for HIV behavioral interventions over time. Effect size shrinkage may
reflect contextual or temporal factors that influence intervention effectiveness (e.g.,
HIV prevention fatigue or reduced fear of HIV post-ART), trends in experimental
design (e.g. MSM subpopulation, choice of comparison group), or underpowered
trials. Potential limitations of current behavioral interventions have been cited in
other studies and argue that behavioral interventions, when implemented alone, are
outdated (Higa et al., 2013; Wolfeiler & Ellen, 2007; Kippax, 2007; Ross & Wight,
2007; Coates et al., 2008; Coates, 2013; Sullivan et al., 2012). This study aimed to
identify the most effective components of behavioral interventions to inform nextgeneration combination approaches. Due to statistical limitations related to
homogeneity, this study used qualitative review to examine potential limitations of
interventions.
Effect of Underpowered Trials
A priori power analysis was not performed for this meta-analysis, and
investigation of post-hoc power was not a study objective. Additionally, assessing
post-hoc power for the primary studies was out of scope for this review, but is a
relevant question for future reviews. Meta-analyses will often have higher power than
the primary studies due how to precision changes in a meta-analysis (Borenstein et al.,
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2009). Trialists across various fields are encouraged to conduct a priori power
analyses to ensure at least 80 percent power to detect an effect. However, many trials
do not report a priori power analysis for sample specification, or do not achieve 80
percent power upon post-hoc analysis (Borenstein et al., 2009). Underpowered trials
are a particular problem for intervention research using small samples. Reviews of the
psychological literature have demonstrated improved overall power in trials over time,
but trials examining small effects remain persistently underpowered (Rossi, 1990;
Maddock & Rossi, 2001).
A recent review of 14,866 meta-analyses in 1,991 Cochrane reviews
calculated power per study in each meta-analysis and found that 70 percent of
Cochrane meta-analyses were underpowered (Turner, Bird, & Higgins, 2013). Of the
34 trials reviewed in this study, less than one third of trial manuscripts (k=10) reported
an a priori power analysis at 80 percent for primary outcomes. Lack of reporting of
power analysis does not necessarily imply that one was not performed or that power
was low, but highlights the need for more transparent reporting in RCTs. Many
studies did not specify the primary outcome, and results extracted for meta-analysis
may have been for a secondary outcome that was not adequately powered, and thus
not appropriate for meta-analysis (Turner et al., 2013).
Finally, CDC efficacy criteria specify a minimum threshold of 40 subjects per
intervention and comparison arm (CDC, 2014c) to be classified as an evidence-based
intervention. Most trials in this study met this criterion, and only four did not.
Further review of RCTs for evidence-based behavioral interventions may benefit from
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post-hoc analyses similar to Turner et al., 2013 and Rossi (1990) to determine if a
general guideline of 40 participants per arm adequately assesses power for the primary
study outcome.
Post-ART and HIV Prevention Fatigue
This study found that most trials (k=23) were conducted after the introduction
of antiretroviral therapy (HIV medications) in 1996 (post-ART). Eleven trials were
conducted pre-ART. Trials conducted later in time are more likely to face contextual
challenges related to HIV prevention fatigue or ART-optimism. ART-optimism is
when high-risk individuals become less concerned about HIV infection because of the
disruptive success of ART; HIV prevention fatigue describes the attitude that HIV
prevention has become tiresome and leads to fatigue in maintaining safer sex
behaviors over time (Ostrow et al., 2002; Stockman et al., 2004).
Distribution of pre- and post-ART trials in this study are different than in
Johnson’s 2008 review. This is mostly due to more MSM-specific trials conducted
after 1996 (82 percent), and a high number conducted 2010 or later (44 percent).
Johnson’s review protocol resulted in trials being about equally distributed between
pre- and post-ART years (24 and 23 respectively). While neither meta-analysis found
pre- or post-ART to be a significant moderator of effect, early pre-ART interventions
were associated with the most successful examples of behavior change resulting in
dramatic decreases in HIV incidence (Coates et al., 2008; Wohlfeiler & Ellen, 2007).
Within 10 years, this effect has decreased (Wohlfeiler & Ellen 2007). It is not known
if pre-ART trials, or even trials older than 5-10 years, would be effective among

85

current MSM. This observation raises important questions about the need for
replication studies of all trials deemed to be evidence-based, especially when these
trials used small samples, but continue to be recommended in public health practice.
Inclusion Criteria or MSM Subpopulation
Higa (2013) suggested that HIV prevention research is more now challenging
than previously due to an increased focus on enrolling the highest risk MSM for
behavioral interventions. Current recommendations suggest targeting MSM at the
highest risk of HIV acquisition and transmission. As many other MSM of lower risk
have benefited from behavioral interventions, the remaining at-risk MSM subgroups
continue to challenge the limits of current interventions due to complex risk factors
not easily addressed by short-term interventions. Priority MSM subgroups include
substance using MSM, black and Latino MSM, young MSM, HIV-positive MSM, and
sexually high-risk MSM. All priority MSM subgroups experience “syndemics.”
Syndemics are defined by “a set of enmeshed and mutually enhancing health problems
that working together in a context of deleterious social and physical conditions
increase vulnerability, significantly affect the overall disease status of a population”
(Singer, 2010). Current behavioral interventions generally cannot address structural or
other risk factors that contribute to syndemics such as poverty, stigma and
discrimination, health care access, and mental health. These unaddressed risk factors
contribute to ongoing sexual risk, and interventions demonstrated to be effective in the
research setting are unlikely to produce sustained effects due to social or economic
inequities that persist beyond the intervention period.
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Comparison Condition
Johnson (2008) found interventions to decrease unprotected anal intercourse by
27 percent when compared to non-HIV related controls, and by 17 percent when
compared with HIV-related controls. This study found that effect size did not
statistically differ by control condition. Interventions using non-HIV related controls
decreased UAI by six percent, interventions using HIV-related controls decreased UAI
by 14 percent, and interventions using wait list controls decreased UAI by 19 percent.
Most trials used an HIV-related control (k=17) or a wait-list control (k=10), and only
seven trials used non-HIV related control.

In Johnson’s review, 65 percent of trials

used non-HIV related controls. This discrepancy suggests that more recent trials
designed exclusively for MSM are more likely to choose an HIV-related control. This
observation is supported by Higa et al., (2013) who found that wait-list controls
decreased over time, and demand controls using an HIV-related comparison increased.
While there are certain advantages to using a wait-list or non-HIV related
controls for rigorous evaluation (Menza et al., 2010), others argue that use of wait-list
or non-HIV related attention controls is unethical because it withholds potentially
effective treatment conditions from high-risk individuals (Higa et al., 2013).
However, use of better control conditions that essentially use a diluted version of the
intervention may greatly reduce the trial’s ability to detect effects (Crepaz et al., 2015;
Higa et al., 2013). This study found that 21 trials did not find significant results
between groups; however many of these trials did report statistically significant risk
reduction changes in both intervention and comparison groups. While this may be
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attributed to assessment bias, it is also possible that the value of exposure to minimal
or standard HIV-related intervention may be underestimated due to the lack of finding
a “significant positive effect” between groups. HIV prevention research may benefit
from a standardized comparison condition to compare intervention effects across trials
(Crepaz et al., 2015; Higa et al., 2013), as well as further examination into control
group effects.
Integrated Interventions
Only nine trials were classified as “integrated interventions.” Integrated
interventions were defined as interventions that simultaneously address multiple
problem behaviors that share a root cause (e.g. substance use, mental health,
homelessness, stigma) (Crepaz et al., 2015). This study found that integrated
interventions were more common among trials designed for substance users (k=6);
these trials included at least one outcome (other than sexual risk reduction) directly
related to reducing substance use (Harawa et al., 2012; Menza et al., 2010; Parsons et
al., 2014; Picciano et al., 2001; Picciano et al., 2007; Shoptaw et al., 2005). The other
three integrated interventions included additional outcomes related to the receipt of
HIV tests at follow-up (Hirshfield et al., 2012; Odonnell et al., 2014; Wilton et al.,
2009). Of trials with HIV testing outcomes, two were designed for black or Latino
MSM. Consistent with the study hypothesis, most integrated interventions (k=6) were
conducted after the last review in 2007 and suggests an increased use of these
approaches for MSM.
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Integrated interventions are an emerging research priority in the development
of combination prevention approaches for high-risk groups. In 2015, CDC published
a systematic review and meta-analysis that showed positive effects of integrated
interventions for people living with HIV (Crepaz et al., 2015). Their review found
that integrated interventions were effective in reducing sex without condoms, and
showed promise for increasing adherence to HIV medications. At the 2015 National
HIV Prevention Conference, CDC announced that at least two EBIs for MSM had
been adapted to an integrated intervention approach (Collins, 2015). For example,
Many Men, Many Voices (3MV) integrated a new component specific to pre-exposure
prophylaxis (PrEP) for black MSM, and Popular Opinion Leader has integrated
multiple outcomes related to HIV care as well as PrEP initiation and adherence.
However, trial results from these adaptations have not been shared or published.
To our knowledge, there is no systematic review or research synthesis
describing the effects of integrated interventions among high-risk HIV-negative MSM.
This study aimed to understand research trends in using this approach, and
hypothesized that more integrated interventions would be available for review than in
the past review (pre-2008). This study also examined integrated interventions as a
moderator variable and found that integrated interventions were not a significant
moderator of effect (p>.05). However, five of nine trials reported statistically
significant effects on at least one sexual risk behavior outcome (Harawa et al., 2012;
Hirshfield et al., 2012; Odonnell et al., 2014; Parsons et al., 2014; Wilton et al., 2009),
and four of the nine integrated interventions were also classified as EBIs (Harawa et
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al., 2012; Odonnell et al, 2014; Parsons et al., 2014; Wilton et al., 2009).
Demonstration of positive effects among hard-to-reach MSM subpopulations such as
substance users and MSM shows promise for using integrated interventions in
combination prevention approaches, but further research beyond this review is needed.
While this study can offer some descriptive information from its narrative
review, further research synthesis including data from recent EBI adaptations are
required to determine if integrated interventions are effective in reducing sexual risk
behavior among high-risk MSM. As stated previously, most integrated interventions
were conducted after 2008 and this area of research is relatively young. Integrated
interventions have intuitive appeal due to their logical approach in addressing
syndemic factors of HIV risk (Parsons, Grov, & Golub, 2012; Starks, Miller,
Eggleston, & Parsons, 2014). Integrated interventions may also have implementation
benefits since they would likely require fewer intervention sessions than single-target
interventions that address one behavior at a time (Crepaz et al., 2015). However, it is
not yet known if integrated interventions are more effective than single-target
interventions, and if there would be negative effects related to scaling up integrated
interventions. Single-target interventions provide clear evidence about what works
when changing one behavior at a time, and it is not clear if integrated interventions
may dilute any single outcome (Crepaz et al., 2015). Updated reviews that examine
the most recent examples of integrated interventions applied in the field are necessary
to answer these questions.
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Moderator Analyses
Overall, trials seemed to have considerable clinical heterogeneity due to their
diverse intervention components, control conditions, and design variables. However,
an insignificant Q statistic combined with an I2 value less than 25 percent suggested
very little statistical heterogeneity. Heterogeneity this low was not expected, but
homogeneity was also observed in the previous meta-analysis (Johnson et al., 2008).
Lack of observed heterogeneity was disappointing, and restricted this study’s overall
goal to identify factors statistically associated with intervention effectiveness. Lack of
heterogeneity generally indicates that moderator analyses are not warranted, unless
they are hypothesized a priori. However, typical measures of heterogeneity have
some level of uncertainty, or in other words, “lack of evidence of heterogeneity is not
evidence for homogeneity” (Borenstein, Higgins, Rothstein, & Hedges, 2015;
Ioannidis, Patsopoulous, & Evangelou, 2007). Following Johnson et al (2008)’s
example, this study pursued post-hoc analyses despite statistically homogeneous
effects. While results need to be interpreted with caution due to potentially spurious
findings, these data can inform hypotheses for future reviews.
This study used subgroup analyses and meta-regressions to explore
independent variables previously examined by CDC’s Prevention Research Synthesis
reviews. Twenty-two analyses were conducted in total, and four independent
variables were specified a priori. A priori moderators included comparison condition,
retention, time span, and outcome measure. All hypothesized moderators were
insignificant at the p<.05 level (p-values ranged from p=.67 to p=.86). This finding
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was surprising. Eighteen other variables were examined post-hoc. Five were
significant at the p<.05 level (e.g. age, HIV status, education, peer-led, and
intervention-level) and three were significant at the trend level of p<.10 level (e.g.
evidence-level, subpopulation, and retention). All independent variables found to be
significant are supported by context and previous research, and thus warrant further
examination in future meta-analyses. Moderators are presented in order of relevance
to the study’s scope.
Evidence Level
Trials classified as evidence-based interventions (EBIs) as opposed to
Rigorous Non-EBIs, Positive Non-EBIs, and Other Non-EBIs were shown to be most
effective at the trend level (OR=.776, p=.076). Currently, there are 20 EBIs listed for
MSM out of 93 other EBIs in CDC’s Compendium for Evidence-Based Interventions
(CDC, 2014b). Eleven are for HIV-negative MSM, and nine are for HIV-positive
MSM. All 11 EBIs for HIV-negative MSM were included in this review and coded as
EBIs. Ten trials were classified as Positive-Non EBIs (i.e. significant finding, but did
not meet criteria for methodological quality), seven trials were classified as RigorousNon EBIs (i.e. met methodological criteria, but did not find a significant result), and
six trials were classified as Other Non-EBIs.
Consistent with findings from Higa et al. (2013), all Rigorous Non-EBIs were
conducted post-ART, suggesting improved methodological quality over time. When
Rigorous Non-EBIs were compared to EBIs, they were more likely to include higherrisk MSM with multiple vulnerabilities (e.g., substance users and low education).
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Trials enrolling populations with higher baseline risk, and more barriers to behavior
change have greater challenges to demonstrating efficacy compared to trials enrolling
more compliant MSM of low to moderate risk.
Of the 10 trials classified as Positive Non-EBIs, the most frequent reasons for
not achieving EBI or Rigorous classification were: having analytic samples under 40
participants per condition (k=2), having only one immediate follow-up session in both
comparison groups (k=3), having less than 60 percent retention in either comparison
(k=2), or having other methodological fatal flaws (k=3) such as contradictory findings,
considerable missing data, or reassignment of participants. Interestingly, five out of
seven interventions using technology (i.e. internet, telephone) were classified as
Positive Non-EBIs. Technology-based interventions struggle with high loss to follow
up rates, and most did not meet EBI criteria for retention. Other Non-EBIs did not
find a positive effect and they did not meet criteria for methodological quality.
Similar to positive non-EBIs, methodological limitations included analytic samples
with less than 40 participants per condition (k=2), only one immediate follow-up
session (k=2), or having other fatal flaws (k=2).
Age
Trials with higher proportions of younger participants were associated with
greater intervention effects (p<.001). Mean age of all trials was 33.3 (SD=5.4).
Scatter plot of meta-regression result showed that intervention effects declined with
increasing mean age (Figure 8). The effect of age was supported by a separate
subpopulation moderator analysis that examined trials designed for high-risk groups,
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including young MSM. Young MSM were defined as MSM under 30 years of age.
Trend-level results were found for the overall group comparison (p=.09), and post-hoc
analyses revealed that interventions for young MSM (OR=.616) were associated with
larger effects than all other subgroups.
While these findings are hopeful for future trials targeting young MSM, these
findings highlight an important HIV prevention research gap. Only four trials were
designed for young MSM. In the US, HIV infections have increased most among
young MSM aged 13-24. Further, young black MSM account for more new HIV
infections than any other age or race group, and it is estimated that at least 50 percent
of young black MSM will be HIV-positive by the time they turn 35 (CDC, 2014a;
Stall et al., 2009). These results show that younger MSM are willing to participate in
behavioral interventions, and can be effectively recruited for HIV prevention research.
Younger MSM who have had less exposure to behavioral interventions may be more
amenable to sexual risk behavior change than older MSM who experience “HIV
prevention fatigue” (Sullivan et al., 2012). However, there may be other challenges
associated with enrolling young MSM. Trials for younger MSM had smaller sample
sizes than the median sample size (range: 39-113) and retention was lower among this
group compared to other MSM. Only one of four trials for young MSM achieved an
overall retention rate ≥80 percent; the three other trials had retention rates between 56
percent and 79 percent.
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Subpopulation
A four-level independent variable was created to examine the amount of
research allocated to high-risk MSM subpopulations, and then to examine if effects
varied by subpopulation. Subpopulations included young MSM, substance users,
MSM of color, and none. As stated previously, overall results indicated trend-level
significance (p=.09). Interventions designed for substance users (k=6) or MSM of
color (k=9) were less effective than interventions for young MSM (k=4) or none
(k=15).
Over the past ten years, there has been an increase in interventions designed
specifically for black and Latino MSM in an effort to align research with the current
epidemic. Despite an increased research focus, there are few evidence-based
interventions for MSM of color. To date, there are only four EBIs for MSM of color
in CDC’s Compendium; two are for black MSM, one is for Latino MSM, and one is
for Asian/Pacific Islander MSM. As the epidemic shifts to become increasingly
concentrated among Black and Latino MSM, well-funded research agendas will be
essential to develop and test behavioral interventions that work for MSM of color.
Future research in this area should aim to develop interventions guided by a
comprehensive approach to address the social, cultural, and structural factors (i.e.
economic or social inequities) that may influence effectiveness (Sullivan et al., 2012),
as well as factors related to research participation (Hatfield et al., 2010).
Trials focusing on substance-using MSM (SUMSM) have also increased in the
past decade, yet there is only one EBI for SUMSM and it was added in 2015 (Parsons
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et al., 2014). Substance use is well-known to be an important driver of HIV infection
among MSM (Coates et al., 2008; Sullivan et al., 2012). This study found that
interventions were less effective among substance-users than any other groups.
Failure to find significant effects highlights the persistent HIV prevention research
challenge of recruiting, retaining, and demonstrating effects among SUMSM.
Challenges associated with SUMSM provide a clear example of when
behavioral interventions are necessary, but not sufficient. SUMSM are particularly
difficult to engage due to factors directly associated with active substance use (i.e.
homelessness, economic insecurity, sex work, psychological issues). SUMSM
generally have higher baseline risk and more complex risk situations that make
demonstrating sexual behavior change an elusive goal for current interventions.
Behavioral interventions designed for SUMSM may benefit more from focusing on
directly reducing substance use (e.g. contingency management or personalized
cognitive counseling) or decreasing sexual behavior during substance use (Higa et al,
2013; Ostrow & Stall, 2008; Sullivan et al, 2012). In a combination prevention
approach, it is likely that very high-risk SUMSM will require resource-intensive,
individual-level interventions that address syndemic factors (i.e. childhood sexual
abuse, mental health, homelessness) combined with biomedical interventions of pre
and post-exposure prophylaxis (Chesney et al., 2003; Higa et al., 2013).
Peer-Led Interventions
Peer-led interventions were found to be more effective than other interventions
(OR=.676, p=.002). This finding is consistent with Higa’s 2013 review of EBIs; they
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found that six out of nine EBIs were delivered by a peer facilitator. This study found
seven out of 11 EBIs for HIV-negative MSM to be peer-led. Peers may aid in
recruitment and retention, especially for high-risk or socially marginalized MSM who
may not otherwise present for HIV prevention services. Peers may be perceived to be
more credible and trustworthy than other professional facilitators, and can help
increase retention by creating environments that feel non-judgmental, safe, and
comfortable (Higa et al., 2013; Ye et al., 2014). A meta-analysis (Ye et al., 2014) of
15 peer-led interventions to reduce UAI among MSM showed that peer-led
interventions decreased UAI overall, but effects varied by design type with the
weakest effects being observed from RCTs. The evidence supporting peer-led
interventions is very promising, especially for young MSM and MSM of color. More
rigorous research is needed to understand factors related to effective peer-led
interventions, and how peer-led components can best support combination approaches.
HIV Status
Trials were less effective when they had more HIV-positive participants
(p=.02). The impact of HIV status was examined in three ways. First, metaregression analysis of trials with any HIV-positive individuals showed that the effect
size decreased with larger proportions of HIV-positive participants (Figure 10).
Second, HIV status was dichotomized to indicate if the trial sample consisted of 20
percent or more HIV-positive MSM. These results were consistent with metaregression; trials with less than 20 percent had stronger effects (p=.032). Finally, 11
trials excluded HIV-positive participants in their eligibility criteria. In subgroup
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analyses, trials that excluded HIV-positive MSM had larger effects (OR=.765,
Q(2)=9.742, p=.008).
Interventions designed for HIV-positive persons are a key component of CDC
PRS’s new prioritization agenda (CDC, 2015). Eligibility criteria for this study
excluded trials designed exclusively for HIV-positive individuals because those trials
were considered out of scope. However, most trials in this review allowed some
proportion of HIV-positive individuals to enroll. Inclusion of HIV-positive
participants may obscure the intervention’s effect on HIV-negative MSM and
contribute to challenges to demonstrate efficacy. This study’s findings are consistent
with Higa et al. (2013). Their review found that EBIs were more likely to exclusively
focus on HIV-negative MSM. Currently, nine of 20 EBIs for MSM are recommended
for HIV-positive MSM, yet not all were designed specifically for MSM. Previous
meta-analysis suggests that HIV-positive individuals may benefit more from
individual-level interventions rather than group-based, as well as interventions
delivered in a clinical setting where they access other services (Crepaz et al., 2006).
Similar to SUMSM, HIV-positive MSM represent a risk group where behavioral
interventions are necessary, but not sufficient. Combination approaches that address
medication adherence, biomedical options for sexual partners, and structural factors
related to syndemics are necessary for HIV-positive MSM at high risk of transmitting
to partners.
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Education Level
Lower education level was found to be associated with effect size.
Interventions with higher proportions of MSM with a high school education or less
were shown to decrease overall effect size in meta-regression analyses (Figure 9)
(p=.023). Reasons for this finding are not totally clear, but as stated previously, Higa
found that trials with high methodological quality, but non-significant findings (i.e.,
“rigorous non-EBIs), were more likely to include MSM with lower education levels,
as well as more substance users. Education is highly correlated with socioeconomic
status and may indicate syndemics such as social or economic inequities (e.g. food
insecurity, homelessness) that contribute to ongoing risk (van den Berg et al., 2015).
Intervention Level
Community-level interventions (CLIs) were found to be associated with
greater effects (OR=.631, p=.032). Community-level interventions are different than
individual or group-level interventions because they aim to change social norms and
then measure behavior change at the community-level. CLIs are typically betterresourced and able to provide longer-term, multi-level interventions. This study’s
finding is consistent previous reviews demonstrating stronger effects among CLIs
(Herbst et al., 2007; Johnson et al., 2008). It is possible that CLIs may be more
effective than other interventions. CLIs may have more potential to address syndemic
risk, and they may also be able to reach more MSM. Despite their potential reach,
CLIs are usually a low dose intervention on a one-on-one level (i.e. brief encounters,
handing out condoms) and unlikely to sustain individual behavior change. More
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research is needed to answer questions. In this review, there were only three
community-level trials (Kegeles et al., 2006; Kelly et al., 1991; Kelly et al., 1997), and
one trial was a replication study (Kelly et al., 1997).
There was little difference in effect between individual and group-level
interventions. In this study, more trials used group-level interventions (k=17) than
individual-level (k=14). There is some research that suggests group-level
interventions may have unintended negative outcomes for higher-risk MSM
subpopulations because high-risk behaviors can be reinforced by peers met in smallgroup interventions (Johnson et al., 2005). However, evidence describing this effect is
mixed. Crepaz (2006) and Herbst (2007) found individual-level interventions to offer
the most benefit, especially for higher-risk populations requiring more intensive,
tailored interventions such as substance users and HIV-positive MSM. Ye (2014)
found peer-based interventions to only be effective in group-based interventions.
Retention
Trials with <80% retention showed slightly better effects (OR=.775, p=.09)
than trials with better retention. Small sample size and poor retention were common
reasons that trials did not meet criteria for methodological quality. High quality
behavioral interventions targeting higher risk MSM such as substance-using MSM are
likely to experience higher loss to follow up. Additionally, 50 percent of trials in this
study reported use of an intention-to-treat (ITT) design; ITT designs are more likely to
underestimate the effect when attrition is high and may further challenge
demonstrations of efficacy. Finally, most trials used follow-up periods of more than 3
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months (k=23), and 16 trials used follow-up periods of 12 months or more. However,
median intervention time span was only three weeks. Follow-up periods that extend
well beyond intervention termination are unlikely to demonstrate efficacy, especially
among MSM subgroups that experience structural-level stressors, substance use, or
mental health issues.
Implications
Despite a smaller than expected effect size, these results indicate that
behavioral interventions continue to show some benefit for MSM. It is generally
accepted that behavioral interventions are too small to decrease HIV incidence, but
they can effectively reduce sexual risk behaviors over the short-term. Results from
this study show that the effect size declined over time, challenging what is known
about the relevance of behavioral interventions to reduce sexual risk behaviors. Over
time, the effect size has gradually decreased and suggests that these interventions may
soon be outdated if they are not improved.
To our knowledge, this is the first study that has examined effect size
shrinkage of HIV behavioral interventions for MSM using cumulative meta-analysis.
These summary findings lend strong support to arguments that behavioral
interventions (and behavioral science) need to do better to improve effectiveness in the
current social and political context. Further research, and future funding, is required
to explain the most important reasons for effect size shrinkage, conduct replication
studies to retire outdated components, and identify the most relevant and promising
intervention features to use in combination approaches.
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Qualitative review of presumably high-quality RCTs revealed lower
methodological quality than expected and highlights limitations of the current
evidence base. These findings are consistent with findings from CDC’s Prevention
Research Synthesis team (Higa et al., 2013). Despite 25 years of prevention research
with MSM, there are only 11 out of 93 EBIs in the entire Compendium for HIVnegative MSM (an additional nine are for HIV-positive MSM) even though MSM are
the most epidemiologically important risk group. Higa et al. (2013) described
methodological challenges to demonstrating efficacy among MSM, but also pointed to
misaligned funding priorities that result in the underfunding of high-quality research
for MSM. Trials published after 2010 were less likely to have reporting biases or fatal
flaws, and trials published after 2010 make up about half of trials eligible for this
review. However, more than half of eligible trials were published prior to 2010 and
influenced the overall effect size. In addition to efforts to make interventions work
better, the research community would benefit from HIV prevention research standards
that require high methodological quality (e.g., a priori power analyses, minimal
retention requirements in both arms, criteria for missing data, replication studies, and
required trial registration), standardized comparison across studies (e.g., similar
outcome measures, standard control groups), and transparent reporting of results to
facilitate high-quality research syntheses (e.g., CONSORT requirements; raw means
and values).
This review found that trials using “integrated interventions” increased since
2008. Results suggest that intervening on and measuring diverse outcomes is feasible
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and relevant for HIV-negative MSM. Future primary trials that use integrated
approaches may be more efficient for HIV prevention because they can target multiple
behavioral drivers of HIV risk among MSM. Integrated behavioral interventions used
in combination with the most relevant biomedical strategies (e.g., interventions that
decrease substance use and sexual risk behaviors with the additive benefit of PrEP for
substance-using MSM) have high potential to curb HIV infection among high-risk
MSM subgroups. Further research is needed to evaluate the effects of these
approaches in real-world settings.
More research is needed to better understand how to use HIV behavioral
interventions that support combination prevention approaches. A primary aim of this
study was to re-evaluate HIV behavioral interventions in the context of new
recommendations for combination approaches and identify the most promising factors
associated with effectiveness. This was not possible due to unexpected statistical
homogeneity. Combination prevention approaches are expected to focus intensive
efforts on HIV subpopulations most at risk for HIV. Future research syntheses may
benefit from narrowing the scope of reviews to focus on only these MSM
subpopulations, and excluding MSM included in earlier trials that are no longer
prioritized for HIV prevention interventions (i.e., white, older MSM of low to
moderate HIV risk).
This review found that some priority MSM subpopulations were underrepresented in current HIV research. Most notably, young MSM comprise the
majority of new infections among MSM, but only accounted for 12 percent of eligible
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trials. Six trials, or only 18 percent, were designed for substance-using MSM; nine
trials, or 26 percent, were designed for MSM of color; and only one trial was
specifically designed for MSM who are behaviorally bisexual (also have sex with
women). There were no interventions specifically designed for emerging MSM
subpopulations such as male sex workers or transgender women (who are sometimes
classified under MSM). There were no RCTs designed for couple-level interventions.
These findings highlight important research gaps. The research base is limited in its
ability to examine how behavioral interventions would benefit emerging and priority
subpopulations. Future primary trials need to prioritize the highest risk MSM.
Research standards that set minimum risk requirements for inclusion should be
established to ensure only high-risk MSM are enrolled in prevention trials.
Limitations
Findings must be interpreted within the context of this study’s limitations.
First, this study used a protocol that was very narrow in scope, and findings may not
be perfectly comparable to other meta-analyses that included HIV-positive MSM,
adolescent MSM, or MSM outside of the United States. Variation in study protocols
and subjective decision-making throughout the research synthesis process can weaken
the validity of comparisons between reviews and lead to spurious results (Ekkekakis,
2015). Future reviews in HIV prevention research should be guided by a standardized
protocol so that the evidence for behavioral interventions can be regularly updated and
compared to past reviews.
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Second, a systematic review and meta-analysis cannot compensate for trials of
low methodological quality. Trials published after 2010 showed higher quality than
earlier trials, most likely resulting from trends in the research field such as the
CONSORT statement (CONSORT, 2010). Earlier trials had more methodological
flaws and higher reporting bias. Most early trials had some level of missing data or
did not clearly report outcomes, statistical analyses, basic statistical information to
calculate effect sizes (e.g., sample sizes by study arm; standard deviations), ITT,
demographic information, or study procedures. This study excluded trials with
missing data after attempts were made to contact study authors, resulting in a reduced
set of trials for review. Additionally, many trials did not report a priori power
analyses, and it is possible that many primary trials were underpowered. Future trials
should aim to improve transparency in reporting to facilitate future evaluations of
prevention research.
Third, sexual risk reduction outcomes are assessed through self-report and may
be vulnerable to social desirability bias or recall bias. Many trials employed methods
to reduce reporting bias such as using computer-assisted assessments or validated
measures such as the Timeline Follow-Back. However, some trials did not clearly
report how the outcome was measured or what procedures were used to increase
confidentiality so as to reduce self-report bias.
Fourth, this study does not represent all MSM in the US. Important MSM
subgroups were under-represented or missing from this review. For example, there
were a surprisingly limited number of studies for young MSM or few studies specific
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to MSM who also have sex with women. There were no studies specific to male sex
workers, and very few trials that even reported the prevalence of male sex work.
Further research on priority subgroups is essential to target behavioral interventions to
the groups at highest epidemiological risk.
Fifth, the independent coder was only able to complete 50 percent of trial
records. While there were few discrepancies, and all were able to be resolved through
consensus, this still suggests threats to validity. Prior to publication, 100 percent of
records will need to be reviewed by at least two coders.
Finally, this study’s largest limitation was its high homogeneity. Lack of
heterogeneity restricted this study from accomplishing its main goal of identifying the
most promising and relevant intervention features of behavioral interventions for next
generation combination approaches. While this study can offer an updated effect size
and estimate of heterogeneity, findings from post-hoc moderator analyses must be
interpreted with caution.
Conclusion
This study found evidence that the overall effect size for MSM-specific HIV
behavioral interventions is still statistically significant. However, the magnitude of the
effect size is considerably smaller than previous reviews, and if this trend continues,
will slowly approach the null value as new trials are added. Gradual effect size
decline over time suggests that behavioral interventions are becoming less effective,
and must evolve to meaningfully contribute to HIV prevention in the current epidemic.
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This study did not find evidence to suggest reliable moderators of
effectiveness. Several variables were found to be potential moderators of effect, but
will require additional research due to their post-hoc nature. Future research would
benefit from further exploring if behavioral interventions are more effective when they
are peer-led or when they have higher proportions of younger MSM. This study
found promising results for the use of integrated behavioral interventions that address
more than one problem behavior. Results suggest that integrated interventions have
become more common in HIV prevention research, especially for high-risk MSM
subgroups (i.e. substance-using MSM), although further research is needed to better
understand how to improve effectiveness.
In conclusion, behavioral interventions remain necessary for HIV prevention
among MSM, but are no longer sufficient. Behavioral interventions do not produce
substantial effects to reduce HIV incidence among MSM, and effect size shrinkage
raises questions about their continued ability to effectively reduce sexual risk
behavior. Behavioral interventions may perform better when used in the context of
new combination approaches, yet further research beyond this study is needed.
To improve behavioral interventions, future research (primary trials and
systematic evaluations) should focus limited research resources on MSM
subpopulations at highest risk of acquiring HIV (i.e., substance users, young MSM,
MSM of color), and aim to identify the most relevant intervention components for the
current epidemic. Replication studies of trials previously identified as effective
interventions are needed to identify intervention components that are outdated and
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need to be retired. Frequent, ongoing systematic reviews and meta-analyses are
required to monitor the effectiveness of new approaches. Future research syntheses in
this field should adopt routine cumulative meta-analysis to better monitor changes in
the effect size as new evidence is accumulated.
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APPENDIX A
EFFECTS OF HIV BEHAVIORAL INTERVENTIONS FOR MEN WHO HAVE SEX WITH
MEN - UNITED STATES, 1988-2014
Systematic Review Search Strategy
Inclusion Criteria
Participants: Adult (<18) US men who have sex with men
Interventions: Any intervention with at least one behavioral sexual risk reduction component that
states HIV prevention as a goal
Comparison: Any control (no treatment, usual care, attention control, another treatment)
Outcomes: Behavioral and biological outcomes.
Study design: Randomized controlled trials in which participants were prospectively assigned to study
groups and in which control group outcomes were measured concurrently with intervention group
outcomes.
Exclusion Criteria
Participants: Individuals who live outside the US, adolescents <18, 100% HIV-positive samples
Study design: Any study without a contemporaneous control group
Filter: No filters except date (January 1, 1988 – current date)
Search String 1. MSM terms (population filter): MSM, men who have sex with men, gay, homosexual,
bisexual, transgender
Search String 2. HIV terms (disease filter): HIV, AIDS, STD (MeSH subheading prevention & control
when available)
Search String 3. Cochrane published RCT filter (study design filter): (randomized controlled trial [pt]
OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR
randomly [tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans [mh])
Databases
1. PubMed
2. EMBASE
3. CENTRAL
4. PsycINFO
5. CINAHL
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PUBMED
Searched 04/26/15
Limits: Publication Date 1988-2015
Notes: Export by batch to Endnote (50 at a time); Delete “search” and post-script, filters, sort by, etc.
when re-running. Sort by Pub Date. Export 500 per time to EndNote.
Search

Query

Items found

#10

Search ((#1) AND #3) AND #7

1208

#9

Search ((#1) AND #3) AND #7 Filters: Publication date from 1988/01/01 to
2015/12/31 Sort by: PublicationDate

1208

#8

Search (((randomized controlled trial [pt] OR controlled clinical trial [pt] OR
randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly
[tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans
[mh])))

3064779

#7

Search (((randomized controlled trial [pt] OR controlled clinical trial [pt] OR
randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly
[tiab] OR trial [tiab] OR groups [tiab]) NOT (animals [mh] NOT humans
[mh]))) Filters: Publication date from 1988/01/01 to 2015/12/31 Sort by:
PublicationDate

2554293

#6

Search (#1) AND #3

4361

#5

Search (#1) AND #3 Filters: Publication date from 1988/01/01 to
2015/12/31 Sort by: PublicationDate

4361

#4

Search ((((((((((("HIV Infections/prevention and control"[Mesh] OR
"Acquired Immunodeficiency Syndrome/prevention and control"[MeSH
Terms] OR "Sexually Transmitted Diseases/prevention and control"[MeSH
Terms]))))))))

50184

#3

Search ((((((((((("HIV Infections/prevention and control"[Mesh] OR
"Acquired Immunodeficiency Syndrome/prevention and control"[MeSH
Terms] OR "Sexually Transmitted Diseases/prevention and control"[MeSH
Terms])))))))) Filters: Publication date from 1988/01/01 to 2015/12/31 Sort
by: PublicationDate

46377
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#2

Search ((((((((("men"[MeSH Terms] OR "men"[All Fields]) AND who[All
Fields] AND ("sex"[MeSH Terms] OR "sex"[All Fields]) AND
("men"[MeSH Terms] OR "men"[All Fields])) OR "msm"[All Fields])) OR
"men who have sex with men"[All Fields]) OR ("homosexuality,
male"[MeSH Terms] OR ("homosexuality"[All Fields] AND "male"[All
Fields]) OR "male homosexuality"[All Fields] OR "gay"[All Fields])) OR
("bisexuality"[MeSH Terms] OR "bisexuality"[All Fields] OR
"bisexual"[All Fields])) OR ("homosexuality"[MeSH Terms] OR
"homosexuality"[All Fields] OR "homosexual"[All Fields])) OR
("transgendered persons"[MeSH Terms] OR ("transgendered"[All Fields]
AND "persons"[All Fields]) OR "transgendered persons"[All Fields] OR
"transgender"[All Fields])))

61967

#1

Search ((((((((("men"[MeSH Terms] OR "men"[All Fields]) AND who[All
Fields] AND ("sex"[MeSH Terms] OR "sex"[All Fields]) AND
("men"[MeSH Terms] OR "men"[All Fields])) OR "msm"[All Fields])) OR
"men who have sex with men"[All Fields]) OR ("homosexuality,
male"[MeSH Terms] OR ("homosexuality"[All Fields] AND "male"[All
Fields]) OR "male homosexuality"[All Fields] OR "gay"[All Fields])) OR
("bisexuality"[MeSH Terms] OR "bisexuality"[All Fields] OR
"bisexual"[All Fields])) OR ("homosexuality"[MeSH Terms] OR
"homosexuality"[All Fields] OR "homosexual"[All Fields])) OR
("transgendered persons"[MeSH Terms] OR ("transgendered"[All Fields]
AND "persons"[All Fields]) OR "transgendered persons"[All Fields] OR
"transgender"[All Fields]))) Filters: Publication date from 1988/01/01 to
2015/12/31 Sort by: PublicationDate

52369
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EMBASE
Searched 04/26/15
Limits: Publication Date 1988-2015
Notes: Sorts by Pub Year by default; export records to CSV and RIS (EndNote); provides detailed
queries upon export that specify contents of combined searches (i.e. #1 AND #3; #6 is complete final
string)
No.

#6

#5

Query EMBASE 04/26/15

Results

'men who have sex with men'/exp OR 'men who have sex with men' OR
'homosexual male'/exp OR 'homosexual male' OR 'homosexuality'/exp OR
'homosexuality' OR 'male homosexuality'/exp OR 'male homosexuality' OR
'bisexual male'/exp OR 'bisexual male' OR 'bisexuality'/exp OR 'bisexuality' OR
'transgender'/exp OR 'transgender' OR 'msm' OR 'gay' AND ('sexually transmitted
diseases'/exp/dm_pc OR 'acquired immunodeficiency syndrome'/exp/dm_pc OR
'human immunodeficiency virus infection'/exp/dm_pc) AND ('randomized
controlled trial'/exp OR 'randomized controlled trial' OR 'controlled clinical
trial'/exp OR 'controlled clinical trial' OR randomized:ti OR randomized:ab OR
placebo:it OR placebo:ab OR randomly:it OR randomly:ab OR groups:it OR
groups:ab OR trial:it OR trial:ab OR 'drug therapy'/de OR 'intervention study'/de)
NOT ('animals'/exp OR animals NOT ('humans'/exp OR humans)) AND (1988:py
OR 1989:py OR 1990:py OR 1991:py OR 1992:py OR 1993:py OR 1994:py OR
1995:py OR 1996:py OR 1997:py OR 1998:py OR 1999:py OR 2000:py OR
2001:py OR 2002:py OR 2003:py OR 2004:py OR 2005:py OR 2006:py OR
2007:py OR 2008:py OR 2009:py OR 2010:py OR 2011:py OR 2012:py OR
2013:py OR 2014:py OR 2015:py)
'men who have sex with men'/exp OR 'men who have sex with men' OR
'homosexual male'/exp OR 'homosexual male' OR 'homosexuality'/exp OR
'homosexuality' OR 'male homosexuality'/exp OR 'male homosexuality' OR
'bisexual male'/exp OR 'bisexual male' OR 'bisexuality'/exp OR 'bisexuality' OR
'transgender'/exp OR 'transgender' OR 'msm' OR 'gay' AND ('sexually transmitted
diseases'/exp/dm_pc OR 'acquired immunodeficiency syndrome'/exp/dm_pc OR
'human immunodeficiency virus infection'/exp/dm_pc) AND ('randomized
controlled trial'/exp OR 'randomized controlled trial' OR 'controlled clinical
trial'/exp OR 'controlled clinical trial' OR randomized:ti OR randomized:ab OR
placebo:it OR placebo:ab OR randomly:it OR randomly:ab OR groups:it OR
groups:ab OR trial:it OR trial:ab OR 'drug therapy'/de OR 'intervention study'/de)
NOT ('animals'/exp OR animals NOT ('humans'/exp OR humans))

112

766

773

#4

'randomized controlled trial'/exp OR 'randomized controlled trial' OR 'controlled
clinical trial'/exp OR 'controlled clinical trial' OR randomized:ti OR
randomized:ab OR placebo:it OR placebo:ab OR randomly:it OR randomly:ab
OR groups:it OR groups:ab OR trial:it OR trial:ab OR 'drug therapy'/de OR
'intervention study'/de NOT ('animals'/exp OR animals NOT ('humans'/exp OR
humans))

#3

'men who have sex with men'/exp OR 'men who have sex with men' OR
'homosexual male'/exp OR 'homosexual male' OR 'homosexuality'/exp OR
'homosexuality' OR 'male homosexuality'/exp OR 'male homosexuality' OR
'bisexual male'/exp OR 'bisexual male' OR 'bisexuality'/exp OR 'bisexuality' OR
'transgender'/exp OR 'transgender' OR 'msm' OR 'gay' AND ('sexually transmitted
diseases'/exp/dm_pc OR 'acquired immunodeficiency syndrome'/exp/dm_pc OR
'human immunodeficiency virus infection'/exp/dm_pc)

3648

#2

'sexually transmitted diseases'/exp/dm_pc OR 'acquired immunodeficiency
syndrome'/exp/dm_pc OR 'human immunodeficiency virus infection'/exp/dm_pc

47878

#1

'men who have sex with men'/exp OR 'men who have sex with men' OR
'homosexual male'/exp OR 'homosexual male' OR 'homosexuality'/exp OR
'homosexuality' OR 'male homosexuality'/exp OR 'male homosexuality' OR
'bisexual male'/exp OR 'bisexual male' OR 'bisexuality'/exp OR 'bisexuality' OR
'transgender'/exp OR 'transgender' OR 'msm' OR 'gay'

49275

113

2734764

CENTRAL
Searched 04/26/15
Limits: Publication Year 1988-2015, Clinical Trials
Notes: Do not use RCT filter; use MeSH terms when possible; Export to txt file with title and abstract
1

MeSH descriptor: [HIV Infections] explode all trees and with qualifier(s): [Prevention
& control - PC]

1944

2

MeSH descriptor: [Acquired Immunodeficiency Syndrome] explode all trees and with
qualifier(s): [Prevention & control - PC]

228

3

2172

4

MeSH descriptor: [Sexually Transmitted Diseases] explode all trees and with
qualifier(s): [Prevention & control - PC]
#1 or #2 or #3 Publication Year from 1988 to 2015, in Trials

5

"MEN WHO HAVE SEX WITH MEN" or "MSM"

447

6

MeSH descriptor: [Homosexuality, Male] explode all trees

233

7

HOMOSEXUALITY and MALE

373

8

"MALE HOMOSEXUALITY"

18

9

MeSH descriptor: [Homosexuality] explode all trees

338

10

HOMOSEXUALITY or HOMOSEXUAL

543

11

MeSH descriptor: [Bisexuality] explode all trees

43

12

BISEXUALITY or BISEXUAL

133

13

MeSH descriptor: [Transgendered Persons] explode all trees

2

14

"TRANSGENDERED" and "PERSONS" or "TRANSGENDERED PERSONS" or
TRANSGENDER
GAY

36

#5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 Publication Year
from 1988 to 2015, in Trials
#4 and #16 Publication Year from 1988 to 2015, in Trials

827

15
16
17

114

1875

469
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PSYCINFO
Searched 04/26/15
Limits: 1988-2015
Notes: Unable to use MeSH terms specific to DISEASE prevention & control resulting in a more
sensitive string with more hits; view all in abstract view, 50 per page, and then save to folder 50 at a
time. Export entire folder to EndNote. Save hyperlink with search string.
S1

"men who have sex with men" OR "msm" OR "homosexual" OR "male
homosexuality" OR "homosexuality" OR ("homosexual” AND “male") OR "gay"
OR “gay men” OR (“gay” AND “men”) OR “bisexual” OR ("bisexual” AND
“men") OR "bisexuality" OR "transgender persons" OR ("transgender" AND
"persons") OR "transgender" OR (((ZU "homosexuality")) or ((ZU "bisexuality")))
or ((ZU "transgender"))

27,805

S2

(((ZU "hiv")) or ((ZU "aids") or (ZU "aids prevention"))) or ((ZU "sexually
transmitted diseases"))

38,015

S3

( PT randomized controlled trials OR PT controlled clinical trials OR TI randomized
OR AB randomized OR TI placebo OR AB placebo OR AB trial OR TI randomly
OR AB randomly OR TI groups OR AB groups OR TI trial ) OR DE drug therapy
NOT ( (animals NOT humans))

877,947

S4

#S1 AND #S2

5,794

S5

#S4 AND #S3

1,803
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CINAHL
Searched 04/27/15
Limits: 1988-2015
Notes: Unable to use MeSH terms specific to DISEASE prevention & control resulting in a more
sensitive string with more hits; view all in abstract view, 50 per page, and then save to folder 50 at a
time. Export entire folder to EndNote. Same platform as psycINFO.

S1

( "men who have sex with men" OR "msm" OR "homosexual" OR "male homosexuality"
OR "homosexuality" OR ("homosexual” AND “male") OR "gay" OR “gay men” OR
(“gay” AND “men”) OR “bisexual” OR ("bisexual” AND “men") OR "bisexuality" OR
"transgender persons" OR ("transgender" AND "persons") OR "transgender" ) OR ( (MH
"Homosexuality+") OR (MH "Homosexuals+") OR (MH "Homosexuals, Male+") ) OR (
(MH "Bisexuality+") OR (MH "Bisexuals+ ") ) OR (MH "Transgendered Persons+")

9,247

S2

(MH "Human Immunodeficiency Virus+") OR (MH "Acquired Immunodeficiency
Syndrome/PC") OR (MH "Sexually Transmitted Diseases+/PC")

19,371

S3

#S1 AND# S2

1,523

S4

(MH "Clinical Trials") OR (MH "Community Trials") OR (MH "Randomized Controlled
Trials") OR (MH "Preventive Trials") OR (MH "Intervention Trials") OR TI randomized
OR AB randomized OR TI placebo OR AB placebo OR AB trial OR TI randomly OR AB
randomly OR TI groups OR AB groups OR TI trial OR DE drug therapy NOT ( (animals
NOT humans))
#S3 AND #S4

292,348

S5

116

245

APPENDIX B: STUDY PROTOCOL

Study ID#
(add report ID# if more than 1
report from same study)
Date of Review
Coder Initials
Author Last Name
Year
Key Words
Notes (if any)
ELIGIBILITY REVIEW. IF NO TO
ANY QUESTION=NOT ELIGIBLE.
STOP REVIEW.
Is this study published in a
peer-reviewed journal?
(yes/no)
Was this study specifically
designed for MSM (y/n)

Are adult US MSM the primary
study population? (y/n)

Use pre-specified study ID# from coding assignment
tab (example: 01). If a study is identified as having
multiple reports, use a report ID# (Example 01-A; use
a letter).
The date you conducted the review (e.g. 08/07/15)
Your initials (e.g. EL - Elsa Larson)
Author's last name for reference
Year of publication
Provide 3-5 key words that you think are important
to describe this article (i.e. bisexual men,
methampethamine-users, internet-based
intervention, young black MSM, etc).
Notes/concerns/questions for this article
The following questions are the eligibility criteria for
the review. If NO to any question, STOP review.
Note reason why.
Identify journal name and confirm it uses a peerreview process
Did the authors describe they designed this for MSM,
and tested it on MSM?
Are U.S. MSM over 18 the primary study population,
>95%? MSM may be of any race/ethnicity, sexual
identity, or HIV-status, etc. Exclude studies that
focus on non-US MSM, adolescents (<18). If mean
age is 18 or older, include.
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Is this study a behavioral
intervention? (y/n)

Was this study tested in RCT
with an independent
comparison group? (y/n)

Did this study measure HIV
behavioral or biological
outcomes? (y/n)

100% HIV positive sample?
Include or exclude?
If excluded, why?
NOTES

Scan article to identify if the study is categorized as a
Behavioral intervention. Behavioral Interventions try
to change individual risk behaviors by providing
necessary skills or materials. Intervention methods
might involve modeling or demonstration, roleplaying, or participatory skill development (i.e.
increasing condom use). Behavioral interventions
are different than provision-of-information-only
interventions that try to change knowledge,
attitudes, or norms only (e.g. increasing HIV
knowledge), or environmental interventions that aim
to change the physical or social environment to
promote health and prevent disease (e.g. reducing
stigma). Exclude information-only, environmental,
and pharmaceutical interventions (i.e. PreP)
Include only randomized controlled trials with an
independent comparison group. (i.e. treatment and
control, pre and post measurements for each group).

Include studies that describe HIV prevention, or
behavioral risk reduction, as the primary or
secondary study outcome. HIV prevention outcomes
may be behavioral (e.g. increasing condom use,
decreasing # of sexual partners, etc) or biological
(e.g. HIV/STI incidence or prevalence). Include
studies that may have had a different primary
outcome (e.g. alcohol or substance use behaviors),
but included HIV prevention or behavioral risk
reduction as a secondary outcome.
If 100% of participants were HIV-positive, exclude.
Decision
If you excluded, indicate why the study was not
eligible
Any notes
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Participant Characteristics

If any variable is unclear or not reported, mark
UNCLEAR or NOT REPORTED

Sample size at baseline
(enrollment)

Report N at baseline (enrollment). This may be what
they report in the abstract

Age Range

Report the age range of participants included in the
study (entire sample)

Age (mean)

Report the mean age for the entire sample at
baseline
Report the age standard deviation
Report the age median, if available

Age, SD
age (median)

(%) race/ethnicity - (Black,
Latino/Hispanic, white, other)

% racial/ethnic minority MSM
% HIV-Positive
How was HIV-status assessed?
(%) HS education or less

Report the % of white, black, Asian, Hispanic, etc, for
the entire study sample. Studies will vary in how
they report race and ethnicity. Report Black,
Latino/Hispanic, White, and Other.
Calculate the sum of Hispanic and non-white MSM in
the sample and report as % of minority
race/ethnicity msm represented in the study
Report % of sample that was HIV-positive
How did the authors measure HIV status (i.e. selfreport, testing at baseline?)
Report percent that graduated HS or less than HS.

Would you say this is a very
high-risk MSM sample? (y/n)

In your opinion, do you think this is a high-risk
sample as defined by high numbers of baseline
sexual partners, risky sex and drug activity, high-risk
sexual networks, etc. You do not need to qualify.

% substance users

Report % of study sample who were substance users
(any)

% sex workers/trade sex

Report % of study sample who were sex
workers/traded sex

% MSMW (not identified as
bisexual)
% gay-identified

Report % of study sample who had sex with both
men and women, but did not identify as bisexual
Report % of study sample who identified as gay

% bisexual-identified

Report % of study sample who identified as bisexual
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% mental health or
vicitimization history

Report % of study sample who had mental health
issues, including but not limited to depression,
childhood sexual abuse, lifetime victimization,
mental distress other.

Intervention Characteristics
Any biological outcomes?

Report if the study used biological outcomes as
endpoints

Intervention level (individuallevel, group-level, communitylevel)

Report if the study was an individual-level
intervention (ILI), group-level intervention (GLI), or
community-level intervention (CLI) - as stated in
article - if unclear, mark unclear

Randomized?
N randomized?
Method of
randomization/allocation
Unit of randomization
Unit of analysis
If unit of randomization does
not match unit of analysis, did
authors control for this? E.g.
report intra-class correlation
coefficient?
More than 1 experimental
condition?
comparison/control condition
(description of control)
Classification of control (wait
list control, HIV-related
comparison group, non-HIV
comparison group)
Intervention setting
(Community, clinic, MSM
setting, other)

Were participants randomized to study groups?
(yes, no). If not, report how they were assigned to
arms.
Report N they randomized
How did the authors operationalize the
randomization procedure?
individual, group, community?
individual, group, community?
Report only if unit of randomization and unit of
assignment are different. If they are different, did
authors report that they controlled for it (e.g. intraclass correlation coefficient)?
Note yes/no if study used more than 1 experimental
condition (e.g. two group randomized trial with
control)
Describe the control group in 1-2 words (information
only, usual treatment, general health education, etc)
categorize as wait-list, HIV-related comparison (any
HIV information, etc), non-HIV related (i.e. nutrition
workshop)

Where did the intervention take place?
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Who facilitated the
intervention? (MSM,
professional, paraprofessional)

Who facilitated/delivered the intervention? Was it
another MSM, professional (e.g. mental health
counselor), para-professional (e.g. HIV test
counselor, community outreach worker)?

Peer-led intervention?

Indicate if it was a peer-led intervention. It may not
be explicit, so examine if the known facilitator
matches the participants, if so, then classify as peerled.

Group size? (if GLI)

If GLI - about how many participants in each group?

Intervention time span (# of
weeks from start to finish)

How many weeks did the intervention last from start
to finish? (e.g. 6 weeks, 12 weeks, etc)

Number of sessions

How many total sessions were in the intervention
(e.g. 2, 6, 12)

Number of hours (total time of
intervention)

How many hours (or total time) was the
intervention? (e.g. 3 sessions X 2 hours each = 6
hours total dose)

Last recall period for primary
outcome

What the recall period participants were asked to
use for the last follow-up session? (e.g. ppts asked to
report on last 30 days of sexual behavior=30 days)

Incentives for participation?

Did participants receive incentives for participation?
(yes/no)

Method of outcome
assessment (interview, paper
survey, ACASI, internet survey)
Years conducted
Multi-site or single site?
US region
Intervention Name/Title

How were the outcomes assessed? Use categories:
interview, paper survey, ACASI/CASI, internet survey)
When was the study started and finished? (e.g. 19971998)
If interventions were conducted at one site, list as
single-site. If interventions were conducted across
multiple sites, list as multi-site.
Report US region if known
What did the authors call the intervention? (i.e.
Project RESPECT, Many Men Many Voices - 3MV,
Living Well, etc…). If there is no name, report NR.
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Theory

Did the authors report it was
pilot tested?

Did the authors report a theoretic principle (e.g.
Transtheoretical Model/Stages of Change,
Information-Motivation-Behavior, Social Cognitive
Theory, Motivational Interviewing, etc)? If so, list.
Did the authors describe any pilot testing or
exploratory research prior to intervention launch?

Include more than 1 behavioral Does the study measure outcomes on at least 1
other behavior (other than sexual risk reduction; i.e.
outcome?
substance use, HIV testing)?

Focus on racial/ethnic minority
MSM?
Focus on MSM substance
users?

Did the authors describe any known psychometric
properties of the scale (i.e. previously tested,
cronbach's alpha/reliability coefficients, etc).
yes/no

Other specified subgroup?

Was this intervention designed, tailored to, or
otherwise focused on MSM of color? (yes/no) If yes,
list specific group

Focus on technology? (if yes,
describe)

Did this intervention focus on using technology such
as the Internet, telephones, text messaging, or other
communication channels?

Focus on sexual
communication? (yes/no)

Did this intervention focus on improving or
increasing any kind of sexual communication
between partners (e.g. HIV status disclosure,
condoms, safer sex, etc?

Focus on stigma and
discrimination? (yes/no)

Did the intervention components include
development of individualized risk reduction plans
tailored to the individual?
Did the intervention focus on stigma and
discrimination (related to being gay, or being MSM of
color) in intervention components?

Inclusion Criteria (HIV status,
substance use, UAI,
serodiscordant partner…)

list inclusion criteria as described exactly by the
authors

Focus on individualized risk
reduction plans? (yes/no)

Study Results
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Primary outcome (s)

What is the study's intended outcome? (e.g. increase
condom use). If multiple outcomes, list all; separate
with comma/semi-colon

Any significant positive effects
on outcome/s? (difference
between treatment and
control)

Were the statistical results significant between
groups and in the right direction? Yes/no (e.g.
yes=study showed 26% decrease in UAI that was
statistically significant)

If other interesting results,
describe here (i.e. within
groups differences, etc).
Significance testing based on
α=.05 (or less) and 2-sided
test?

Use this spot to report on other significant or
interesting results including within groups (pre-post
change scores by group), subgroup analyses, etc.
Were significance tests based on .05 alpha level (or
more stringent such as .01) and a two-tailed test?

Aim: reductions in UAI? (list
sig/ns)

If UAI (unprotected anal intercourse) was the
outcome, were outcomes significant (sig) or not
significant (ns)?

Aim: increased condom use?
(sig/ns)
Aim: reduce number of sexual
partners?
Aim reduced substance use?
(sig/ns)
Aim: reduce serodiscordant
sex? (sig/ns)
Aim: reduce receptive sex?
(sig/ns)
Other outcomes (testing,
disclosure, substance use, list
sig/ns)

If condom use was the outcome, were outcomes
significant or not significant?

A priori power analysis
conducted?

Did the authors report that they conducted an a
priori power analysis to specify sample size? If so,
did they specify >80% power?
How many months between T1 and last follow up
(T2)?

Follow-up time used for
analyses (# months after T1)
Analytic sample >40 per
group?
n treatment group at T1
(baseline)

if # of partners was an outcome, were outcomes
significant or not significant?
If substance use was the outcome, were outcomes
significant or not significant?
If serodiscordant sex was the outcome, were
outcomes significant or not significant?
If receptive sex was the outcome, were outcomes
significant or not significant?
If other outcomes were studies such as HIV testing,
disclosure to partners, or substance use, describe
and report if results were sig or ns.

Did the treatment and control groups have at least
40 ppts in each at the time of analysis?
How many ppts in the tx group at T1 (at baseline)?
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n control group at T1
n tx group T2 (follow-up)
n control group T2
% and n - retention at last f/u
% retention tx group (at last
f/u)
% retention in control group
(at last f/u)

How many ppts in the control group at T1 (at
baseline)?
How many ppts in the tx group at T2 (at follow-up)?
How many ppts in the control group at T2 (at followup)?
At the last follow-up, what percent of ppts overall
were retained in the study? (compare overall
baseline to overall f/u and calculate %)
At the last follow-up, what percent of ppts in the tx
group were retained?
At the last follow-up, what percent of ppts in the
control group were retained?

Differential Retention?

Is there differential retention between tx and control
groups?

Baseline differences between
study groups?
If yes, what?
(ITT) Intent-to-treat analysis
(ppts analyzed in original
groups and data replacement
for dropouts)?

Were there baseline differences between the tx and
control groups? Yes/no

Did study provide a CONSORT
statement?

Did the article have an attachment or reference to a
CONSORT statement? (standardized reporting for
RCTs)

Was study a registered trial?

Did the study indicate a trial registration # in the
article or abstract?

Did the authors specify they used an ITT analysis?

Statistical Information

For continuous data analyses
(T1=baseline; T2=final f/u)

Only for interval-level data - skip to categorical
if needed - retrieve baseline (T1) and final
follow/up (T2). Retrieve n for each of the four
groups (baseline tx, baseline control, f/u tx, f/u
control), the group means, and their SD or SE to
calculate effect sizes later. If there are multiple
outcomes (e.g. reduced UAI, reduced substance
use), use multiple rows and list study ID# each
time
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Study ID (use multiple lines for
multiple outcomes)
Specific outcome variable
definition
N analyzed for results
N analyzed in tx group
N analyzed in control group
Means transformed or
adjusted? If so indicate with
red type
N analyzed at T1 - tx group

Mean at T1
(tx group)
SD at T1 (tx group)
SE at T1 (tx group)
N analyzed at T1 - control
group
Mean at T1
(control group)
SD at T1 (control group)
SE at T1 (control group)
N analyzed at T2 - tx group
Mean at T2
(tx group)
SD at T2 (tx group)
SE at T2 (tx group)
N analyzed at T2 - control
group
Mean at T2
(control group)
SD at T2 (control group)
SE at T2 (control group)
Mean Difference Tx group (T1T2)

ID
Describe the outcome as specifically as possible,
matching the authors description
Total N for analytic sample
n for tx group
n for control group
Indicate if any means were transformed or adjusted
with yes/no and then mark the reported adjusted
means with a (*).
n for how many in tx group at time 1
group mean for the tx group at T1
If reported, list standard deviation
if reported, list standard error

n for how many in control group at time 1
(baseline)
group mean for the tx group at T2
If reported, list standard deviation
if reported, list standard error

n for how many in tx group at time 2 (last followup)
What was the follow-up mean for the tx group? (e.g.
mean number of UAI occasions at T1). Use last
possible follow-up.
If reported, list standard deviation
if reported, list standard error

n for how many in control group at time 2 (f/u)
What was the follow-up mean for the control group?
(e.g. mean number of UAI occasions at T1). Use last
possible follow-up.
list standard deviation
list standard error
calculate mean differences; use excel formula
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Mean difference control group
(T1-T2)
Mean Difference (T - C at T2)
correlation pre-post scores
statistical method used
t-value
F statistic
p-value
Df
RR
Beta
SMD
95% CI
Other
Effect size reported
ES type
ES
95% CI for ES

For categorical data analysis

Specific outcome variable
definition
N analyzed tx group

calculate mean differences; use excel formula
calculate mean differences; use excel formula
if reported, otherwise leave blank
Report test used
t-value if reported
F-stat if reported
p-value if reported
df if reported
RR if reported (e.g. ratio of mean # of events in Tx
group to mean # of events in control, see Johnson's
2008 Cochrane review)
betas for any regression models
Standardized mean difference if reported. If unclear,
consult Cochrane definition at:
http://handbook.cochrane.org/chapter_9/9_2_3_2_t
he_standardized_mean_difference.htm
If the authors reported 95% CI for ES, list
Yes/no
type (Cohen’s d, Cohen’s f, etc)
test statistic
95% CI specific to ES

for dichotomous data: Think about constructing
a 2X2 table for each of the four groups; we
need the # or % who reported the outcome
("yes" = ex. this would be the 1 group in a
binary analysis) and the # or % that did NOT
report the outcome ("no"= ex. this would be
the 0 group in a binary analysis). If there are
multiple outcomes (e.g. reduced UAI, reduced
substance use), use multiple rows, and list
study ID# each time.

specific outcome variable, same as continuous
Instructions same as continuous
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N analyzed control group
N analyzed at T1-tx group

Instructions same as continuous
Instructions same as continuous

number for tx group at T1 outcome

If authors reported counts, list number of ppts in tx
group that reported outcome at T1 (e.g. 50 report
any UAI).

number for tx group at T1 - no
outcome

If authors reported counts, list number of ppts in tx
group that reported no outcome at T1 (e.g. 50
reported zero UAI).

proportion for tx group at T1 outcome

If authors reported % or proportion, list number of
ppts in tx group that reported any outcome at T1
(e.g. 50% reported UAI).

If authors reported % or proportion, list number of
ppts in tx group that reported no outcome at T1 (e.g.
50% reported NO UAI).
N analyzed at T1- control group same as continuous

proportion for tx group at T1 no outcome

number for control group at T1
- outcome

If authors reported counts, list number of ppts in
control group that reported outcome at T1 (e.g. 50
report any UAI).

number for control group at T1
- no outcome

If authors reported counts, list number of ppts in
control group that reported no outcome at T1 (e.g.
50 reported zero UAI).

prop. for control group at T1 outcome

If authors reported % or proportion, list % of ppts in
control group that reported any outcome at T1 (e.g.
50% reported UAI).

prop. for control group at T1 no outcome

If authors reported % or proportion, list % of ppts in
control group that reported no outcome at T1 (e.g.
50% reported NO UAI).
Instructions same as continuous

N analyzed at T2-tx group
number for tx group at T2 outcome

If authors reported counts, list number of ppts in tx
group that reported outcome at T2 (e.g. 50 report
any UAI).

number for tx group at T2 - no
outcome

If authors reported counts, list number of ppts in tx
group that reported no outcome at T2 (e.g. 50
reported zero UAI).

prop. for tx group at T2 outcome

If authors reported % or proportion, list % of ppts in
tx group that reported any outcome at T2 (e.g. 50%
reported UAI).
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prop. for tx group at T2 - no
outcome
N analyzed at T2-control group

If authors reported % or proportion, list % of ppts in
tx group that reported no outcome at T2 (e.g. 50%
reported NO UAI).
same as continuous

number for control group at T2
- outcome

If authors reported counts, list number of ppts in
control group that reported outcome at T2 (e.g. 50
report any UAI).

number for control group at T2
- no outcome

If authors reported counts, list number of ppts in
control group that reported no outcome at T2 (e.g.
50 reported zero UAI).

prop. for control group at T2 outcome

If authors reported % or proportion, list number of
ppts in control group that reported any outcome at
T2 (e.g. 50% reported UAI).

prop. for control group at T2 no outcome

If authors reported % or proportion, list number of
ppts in control group that reported no outcome at T2
(e.g. 50% reported NO UAI).
statistical test used
list test stats that are reported
Odds ratio
Relative risk
Prevalence ratio
Risk difference
95% confidence interval
Logged Odds Ratio
Exact p-value
Other
Yes/no
type (Cohen’s d, Cohen’s f, etc)
95% CI for ES
Notes
Refer to PRS criteria
http://www.cdc.gov/hiv/dhap/prb/prs/efficacy/rr/cri
teria/index.html
Is it reported to be an Evidence-Based Intervention?

statistical method used
χ2
OR
RR
PR
Risk Diff
CI
Logged OR
p value
Other
effect size reported?
ES type
95% CI for ES
NOTES
Methodological Quality
Review using PRS Criteria
Is study described as an EBI?
If CDC already classified in
their 2013 review (studies
before 2011), list their ranking

Use Higa et al (2013) when possible
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(EBI, positive non-EBI, rigorous
non-EBI, other non-EBI)
Refer to PRS GOOD criterion
for study's intervention level
(ILI, GLI, CLI): Indicate if study
met all points for each
criterion; if no, list failures.
I. Intervention Description
II. Quality of Study Design
III. Quality of Study
Implementation and Analysis
IV. Strength of Evidence
V. No demonstrated
significant negative
intervention effects
VI. Additional Limitations to
Evaluate
Methodological Quality
Category
EBI:
Met PRS criteria for good and
had positive result
Rigorous Non-EBI:
Met good PRS criteria, but no
positive result
Positive Non-EBI:
Positive Result, but did not
meet at least 1 PRS criteria
Other-Non-EBI:
No positive result, did not
meet at least 1 PRS criterion
Different from CDC rating,
when applicable
NOTES
DONE! STOP.

yes/no
yes/no
yes/no
yes/no
yes/no

yes/no
yes/no

yes/no

yes/no

yes/no

yes/no
Notes
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APPENDIX C
COMPENDIUM OF EVIDENCE-BASED INTERVENTIONS AND BEST PRACTICES
FOR HIV PREVENTION RISK REDUCTION (RR) CHAPTER
Last updated December 3, 2014
PRS Efficacy Criteria for Best-Evidence Risk Reduction (RR) Individual-level, Grouplevel, and Couple-level Interventions (ILIs/GLIs/CPLs)
Intervention Description
 Clear description of key aspects of the intervention
Quality of Study Design
 Prospective study design
 Appropriate and concurrent comparison arm
 Random or minimally biased assignment of subjects to study arms
Quality of Study Implementation and Analysis
 Follow-up assessment ≥ 3-months post completion of intervention for each study arm
with recall not referring to pre-intervention period)
 At least a 70% retention rate at a single follow-up assessment for each study arm
 Comparison between intervention arm and an appropriate comparison arm
 Analysis of participants subjects in study arms as originally allocated regardless of
contamination or logistic/implementation issues
 Analysis of participants regardless of the level of intervention exposure
 Use of appropriate cluster-level analyses if assigned to study arms by cluster or group
 Analysis must be based on post-intervention levels or on pre-post changes in measures
 For pre-post changes used in analysis, measures must be identical, including identical
recall period
 Analysis based on an α =.05 (or more stringent) and a 2-sided test
 With nonrandomized assignment, either no statistical differences in baseline levels of
the outcome exist or baseline differences are controlled for in the analysis
 Analytic sample ≥ 50 participants per study arm
Strength of Evidence
Demonstrated Significant Positive Intervention Effects
 Positive and statistically significant (p < .05) intervention effect for ≥1 relevant
outcome measure
 A positive intervention effect is defined as a greater reduction in HIV/STD incidence
or risk behaviors or a greater increase in HIV protective behaviors in the intervention
arm relative to the comparison arm
 A relevant outcome is defined as a behavior (e.g., abstinence, mutual monogamy,
number of sex partners, consistent condom use with anal/vaginal sex, unprotected
anal/vaginal sex, proportion of anal/vaginal sex acts protected, injection drug use,
sharing or borrowing needles/works) - that directly impacts HIV risk or a biologic
measure indicating HIV or STD infection (i.e., HIV or STD incidence)
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Effect at the follow-up and based on the analyses that meet study implementation and
analysis criteria

No Demonstrated Significant Negative Intervention Effects
 No negative and statistically significant (p < .05) intervention effect for any relevant
outcome
 A negative intervention effect is defined as a greater increase in HIV/STD incidence
or risk behaviors or a greater decrease in HIV protective behaviors in the intervention
arm relative to the comparison arm.
 No other statistically significant harmful intervention effect
 For an intervention with a replication evaluation, no significant negative intervention
effects in the replication study
Additional Limitations to Evaluate
 No evidence that additional limitations resulted in a fatal flaw: o A fatal flaw has
occurred when the overall evaluation of limitations indicates they resulted in
considerable bias, thus substantially reducing the confidence of the findings.
 Examples of
within potentially biased subset analyses;
 Substantial missing data. Missing data plus loss to attrition exceeds acceptable limits
for retention alone (≥ 40%)
 Study arm non-equivalence: statistically significant differences between arms in
important baseline demographics or risk factors
 Differential retention: (1) significant difference between study arms in characteristics
among retained or lost-to-follow up participants; OR (2) more than minimal rate of
differential retention (>10%)
 Intervention activities did not match with the intervention concepts or guiding theories
intended to produce the desired outcomes
 Did not clearly describe issues related to generalizability
 Too many post hoc analyses (even with Bonferroni corrections)
 Inconsistent findings
All criteria must be satisfied for an intervention to be considered as a best-evidence
individual-level, group-level, or couple-level intervention. Source: Lyles et al., (2006) and
Lyles at al., (2007).
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PRS Efficacy Criteria for Best-Evidence Risk Reduction (RR) Community-level
Interventions (CLIs)
Intervention Description
 Clear description of key aspects of the intervention
Quality of Study Design
 Prospective study design
 Appropriate and concurrent control/comparison arm
 ≥ 4 communities per arm or appropriate power analysis indicating that a smaller
number of communities was adequate (i.e., 2 or 3 communities per arm)
 Select similar communities (units) for assignment
 To minimize selection bias before assignment regardless of assignment methods
(randomization or not); use methods such as systematic, a priori approaches to choose
intervention and control communities that are similar (e.g., matching or stratification
on factors related to important/appropriate community characteristics)
Quality of Study Implementation and Analysis
 Sample individuals from assigned communities in acceptable ways (e.g., random,
systematic) and use identical methods and eligibility criteria for selecting participants
in each community, study arm, and data collection wave
 If demographic differences are identified a priori, differential selection (e.g., oversampling based on demographics) may be used to achieve equivalence between study
arms on those factors
 Follow-up assessment ≥ 3 months post completion of entire time-specific CLI or post
full implementation of on-going CLI with recall not referring to pre-intervention
period
 “Post full implementation of an on-going CLI” means after all components of the CLI
have been started or put in place in communities
 If cohort, at least 70% retention rate at a single follow-up assessment for each study
arm
 If cohort chart review, ≥ 70% success rate in matching medical records
 Comparison between intervention arm and an appropriate comparison arm
 Analysis of communities (units) and analysis of individuals within the communities as
originally assigned regardless of contamination or logistic/implementation issues
 Analysis of communities (units) regardless of community level of intervention
exposure
 Analysis of individuals within the communities (units) regardless of individual level
of intervention exposure
 Use of appropriate cluster-level analyses, e.g., adjusting for ICC
 Analysis must be based on post-intervention levels or among pre-post changes in
measures
 For pre-post changes used in analysis, measures must be identical, including identical
recall period
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Analysis based on an a=.05 (or more stringent) and a 2-sided test; either no statistical
differences in baseline levels of the outcome exist or baseline differences are
controlled for in the analysis, regardless of allocation method (e.g., randomization,
non-randomization)
No differences on baseline levels of the outcome means reporting no significant
difference between groups on BL relevant outcomes or match/stratify/statistically
adjust participant data by using propensity scores or relevant outcome covariates
(regardless of assignment methods - RCT or non-RCT)

Strength of Evidence
Demonstrated Significant Positive Intervention Effects
 Positive and statistically significant (p < .05) intervention effect for ≥ 1 relevant
outcome measure
 A positive intervention effect is defined as a greater reduction in HIV/STD incidence
or risk behaviors or a greater increase in HIV protective behaviors in the intervention
arm relative to the comparison arm.
 A relevant outcome is defined as a behavior (e.g., abstinence, mutual monogamy,
number of sex partners, consistent condom use with anal/vaginal sex, unprotected
anal/vaginal sex, proportion of anal/vaginal sex acts protected, injection drug use,
sharing or borrowing needles/works) that directly impacts HIV risk or a biologic
measure indicating HIV or STD infection (i.e., HIV or STD incidence)
 Effect at the follow-up and based on the analyses that meet study implementation and
analysis criteria
No Demonstrated Significant Negative Intervention Effects
 No negative and statistically significant (p < .05) intervention effect for any relevant
outcome
 A negative intervention effect is defined as a greater increase in HIV/STD incidence
or risk behaviors or a greater decrease in HIV protective behaviors in the intervention
arm relative to the comparison arm.
 No other statistically significant harmful intervention effect
 For an intervention with a replication evaluation, no significant negative intervention
effects in the replication study
Additional Limitations to Evaluate
 No evidence that additional limitations resulted in a fatal flaw: o A fatal flaw has
occurred when the overall evaluation of limitations resulted in considerable bias, thus
substantially reducing the confidence of the findings
 Examples of limitations to check for possible fatal flaw: Group non-equivalence in
baseline measures of important demographics or risk factors
 Differential Retention (for cohort studies): (1) association between study arms and
characteristics related to retention or attrition; OR (2) more than minimal rate of
differential retention (> 10%)
 Differential Refusal: At baseline for cohort studies; by wave for serial cross-sectional
studies: (1) association between study arms and characteristics related to refusal; OR
(2) more than minimal rate of differential refusal rate (> 100)
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Intervention activities did not match with the intervention concepts or guiding theories
intended to produce the desired outcomes
Did not clearly describe issues related to generalizability
Effects only found within a potentially biased subset analyses
Substantial missing data (> 10% or missing data plus loss to attrition does not exceed
acceptable limits for retention alone)
Too many post hoc analyses (even with Bonferroni corrections)
Pilot study or very small sample size per study arm (< 50)
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PRS Efficacy Criteria for Good-Evidence
Risk Reduction (RR) Individual-level, Group-level, and Couple-level Interventions
(ILIs/GLIs/CPLs)
Intervention Description
 Clear description of key aspects of the intervention
Quality of Study Design
 Prospective or quasi-prospective study design
 Appropriate and concurrent comparison arm, or historical comparison (provided it is
similar to intervention arm with respect to population, setting, and time frame in the
epidemic, and identical with respect to follow-up interval, recall period, and outcome
measures)
 Random, minimally biased, or moderately biased allocation of participants to study
arms, allowing for selection bias unrelated to the intervention or HIV risk.
Assignment may be based on pre-established groups or selection into something other
than the intervention, provided neither is directly related to HIV risk.
Quality of Study Implementation and Analysis
 Follow-up assessment ≥ 1 month post-completion of intervention for each study arm
with recall not referring to pre-intervention period
 At least a 60% retention rate (or medical chart recovery) at a single follow-up for each
study arm
 Comparison between intervention arm and an appropriate comparison arm
 Analysis of participants in study arms as originally allocated, or contaminated
participants may be excluded if numbers are small, but participants may not be reassigned for analytic purposes
 Analysis of participants may be based on intervention exposure, where participants
exposed to < 50% of the entire intended intervention may be excluded
 If participants excluded due to contamination or low exposure (as described above),
retention rate must include these participants at each follow-up they were assessed
 Analysis must be based on post-intervention levels or on pre-post changes in measures
 For pre-post changes used in analysis, measures must be identical, including identical
recall period
 Analysis based on an α =.05 and either a 2-sided test or 1-sided test if an a priori
direction is hypothesized
 With nonrandomized assignment, either no statistical differences exist in baseline
levels of the outcome measure, or baseline differences must be controlled for in the
analysis. If moderately-biased assignment or historical comparison was used,
differences in baseline demographics also must be controlled for in the analysis.
 Analytic sample of ≥ 40 participants per study arm
Strength of Evidence
Demonstrated Significant Positive Intervention Effects
 Positive and statistically significant (p < .05) intervention effect for ≥ 1 relevant
outcome measures
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A positive intervention effect is defined as a greater reduction in HIV/STD incidence
or risk behaviors or a greater increase in HIV protective behaviors in the intervention
arm relative to the comparison arm.
A relevant outcome is defined as a behavior (e.g., abstinence, mutual monogamy,
number of sex partners, consistent condom use with anal/vaginal sex, unprotected
anal/vaginal sex, proportion of anal/vaginal sex acts protected, injection drug use,
sharing or borrowing needles/works) that directly impacts HIV risk or a biologic
measure indicating HIV or STD infection (i.e., HIV or STD incidence)
Effect at the follow-up and based on the analyses that meet study implementation and
analysis criteria

No Demonstrated Significant Negative Intervention Effects
 No negative and statistically significant (p < .05) intervention effect for any relevant
outcome
 A negative intervention effect is defined as a greater increase in HIV/STD incidence
or risk behaviors or a greater decrease in HIV protective behaviors in the intervention
arm relative to the comparison arm.
 No other statistically significant harmful intervention effect
 For an intervention with a replication evaluation, no significant negative intervention
effects in the replication study
Additional Limitations to Evaluate
 No evidence that additional limitations resulted in a fatal flaw: o A fatal flaw has
occurred when the overall evaluation of limitations indicates they resulted in
considerable bias, thus substantially reducing the confidence of the findings.
 Examples of item limitations to check for possible fatal flaw:
o Effects only found within potentially biased subset analyses
o Substantial missing data: Missing data plus loss to attrition exceeds
acceptable limits for retention alone (≥ 40%)
o Study arm non-equivalence: statistically significant differences between arms
in important baseline demographics or risk factors
o Differential Retention: (1) association between study arms and characteristics
related to retention or attrition; OR (2) more than minimal rate of differential
retention (> 10%)
o Intervention activities did not match with the intervention concepts or guiding
theories intended to produce the desired outcomes
o Did not clearly describe issues related to generalizability
o Too many post hoc analyses (even with Bonferroni corrections)
o Inconsistent findings

All criteria must be satisfied for an intervention to be considered as a good-evidence
individual-level, group-level, or couple-level intervention
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PRS Efficacy Criteria for Good-Evidence Risk Reduction (RR) Community-level
Interventions (CLIs)
Intervention Description
 Clear description of key aspects of the intervention
Quality of Study Design
 Prospective or quasi-prospective study design
 Appropriate and concurrent comparison arm, or historical comparison (provided it is
similar to intervention arm with respect to population, setting, time frame in the
epidemic, and identical with respect to follow-up time, recall period, and outcome
measures)
 Post hoc selection of comparison is allowed
 ≥ 1 community per arm
 1 community per arm is acceptable only if the following conditions are met: (1) there
is a significant pre- and post-intervention change in the relevant outcome for the
intervention arm, and (2) the significant pre- and post-intervention change is based on
appropriate participant-level analysis or repeated-measures analysis.
 Select similar communities (units) for assignment
 To minimize selection bias before assignment regardless of random assignment or
other assignment methods, used methods such as systematic, a priori approaches to
select intervention and comparison communities that are similar (e.g., matching or
stratification on factors related to important/appropriate community characteristics)
Quality of Study Implementation and Analysis
 Sample individuals from assigned communities in acceptable ways (e.g., random,
systematic) and use identical methods and eligibility criteria for selecting participants
in each community, study arm, and data collection wave
 If demographic differences are identified a priori, differential selection (e.g., oversampling based on demographics) may be used to achieve equivalence between study
arms on those factors
 Follow-up assessment ≥ 1 month post completion of entire time-specific CLI or post
full implementation of on-going CLI with recall not referring to pre-intervention
period
 “Post full implementation of on-going CLI” means after all components of the CLI
have been started or put in place in communities
 If cohort, at least 60% retention rate (or medical chart recovery) at a single follow-up
assessment for each study arm
 Comparison between intervention arm and an appropriate comparison arm
 Analysis of communities (units) as originally assigned, or communities may be
excluded due to contamination or logistic/implementation issues only if dropping no
more than one community per study arm AND retaining at least two thirds of intended
communities
 Analysis of individuals within the communities (units) as originally assigned, or
contaminated individuals may be excluded if numbers are small, but individuals may
not be reassigned for analytic purposes
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Analysis of communities (units) regardless of community level of intervention
exposure
Analysis of individuals within the communities (units) may be based on intervention
exposure, where dropping individuals who were not exposed to any intervention
component (e.g., have not heard of or recognized intervention materials) would retain
at least 60% of total sample
Cluster-level analyses may be provided, but is not required
Analysis must be based on post-intervention levels or among pre-post changes in
measures
For pre-post changes used in analysis, measures must be identical, including identical
recall period
Analysis based on an α =.05 and either a 2-sided test or 1-sided test if an a-priori
direction is hypothesized
Either no statistical differences in baseline levels of the outcome exist or baseline
differences are controlled for in the analysis, regardless of allocation method (e.g.,
randomization, non-randomization)
No differences on baseline levels of the outcome means reporting no significant
difference between study arms in baseline relevant outcome measures, or
match/stratify/statistically adjust participant data by using propensity scores or
relevant outcome covariates (regardless of assignment methods – RCT or non-RCT)

Strength of Evidence
Demonstrated Significant Positive Intervention Effects
 Positive and statistically significant (p < .05) intervention effect for ≥ 1 relevant
outcome measure
 A positive intervention effect is defined as a greater reduction in HIV/STD incidence
or risk behaviors or a greater increase in HIV protective behaviors in the intervention
arm relative to the comparison arm
 A relevant outcome is defined as a behavior (e.g., abstinence, mutual monogamy,
number of sex partners, consistent condom use with anal/vaginal sex, unprotected
anal/vaginal sex, proportion of anal/vaginal sex acts protected, injection drug use,
sharing or borrowing needles/works) that directly impacts HIV risk or a biologic
measure indicating HIV or STD infection (i.e., HIV or STD incidence)
 Effect at the follow-up and based on the analyses that meet study implementation and
analysis criteria
No Demonstrated Significant Negative Intervention Effects
 No negative and statistically significant (p < .05) intervention effect for any relevant
outcome
 A negative intervention effect is defined as a greater increase in HIV/STD incidence
or risk behaviors or a greater decrease in HIV protective behaviors in the intervention
arm relative to the comparison arm
 No other statistically significant harmful intervention effect
Additional Limitations to Evaluate
 No evidence that additional limitations resulted in a fatal flaw:
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A fatal flaw has occurred when the overall evaluation of limitations indicate they
resulted in considerable bias, thus substantially reducing the confidence of the
findings
Examples of limitations to check for possible fatal flaw:
 Study arm non-equivalence: statistically significant differences between arms in
important baseline demographics or risk factors
 Differential Retention (for cohort studies): (1) association between study arms and
characteristics related to retention or attrition; OR (2) more than minimal rate of
differential retention (> 10%)
 Differential Refusal – at baseline for cohort studies; by wave for serial crosssectional studies: (1) association between study arms and characteristics related to
refusal; OR (2) more than minimal rate of differential refusal rate (> 10%)
 Intervention activities did not match with the intervention concepts or guiding
theories intended to produce the desired outcomes
 Did not clearly describe issues related to generalizability
 Effects only found within potentially biased subset analyses
 Substantial missing data (> 10%, or missing data plus loss to attrition exceeds
acceptable limits for retention alone)
 Too many post hoc analyses (even with Bonferroni corrections)
 Pilot study or very small sample size per study arm (< 40)
 Inconsistent findings
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